<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Altered dietary salt intake for preventing diabetic kidney disease and its progression - Hodson, EM - 2023 | Cochrane Library</title> <meta content="Altered dietary salt intake for preventing diabetic kidney disease and its progression - Hodson, EM - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006763.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Altered dietary salt intake for preventing diabetic kidney disease and its progression - Hodson, EM - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006763.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006763.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Altered dietary salt intake for preventing diabetic kidney disease and its progression" name="citation_title"/> <meta content="Elisabeth M Hodson" name="citation_author"/> <meta content="emhodson@exemail.com.au" name="citation_author_email"/> <meta content="Tess E Cooper" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD006763.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/01/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006763.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006763.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006763.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Diabetes Mellitus, Type 1; *Diabetes Mellitus, Type 2 [complications, prevention &amp; control]; *Diabetic Nephropathies [prevention &amp; control]; *Hypertension [drug therapy]; *Renal Insufficiency, Chronic [prevention &amp; control]; Sodium; Sodium Chloride, Dietary [adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006763.pub3&amp;doi=10.1002/14651858.CD006763.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="p32VIvbS";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006763\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006763\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006763\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006763\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ko","pt","ms","hr","fr","zh_HANT","th","ja","fa","id","nl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006763.pub3",title:"Altered dietary salt intake for preventing diabetic kidney disease and its progression",firstPublishedDate:"Jan 16, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006763.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006763.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006763.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006763.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006763.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006763.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;nl&quot;,&quot;title&quot;:&quot;Samenvatting in eenvoudige taal&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006763.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006763.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006763.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006763.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4324 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006763.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full#CD006763-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full#CD006763-sec-0088"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full#CD006763-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full#CD006763-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full#CD006763-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full#CD006763-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full#CD006763-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full#CD006763-sec-0082"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/appendices#CD006763-sec-0093"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/supinfo/CD006763StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/supinfo/CD006763StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Altered dietary salt intake for preventing diabetic kidney disease and its progression</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/information#CD006763-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Elisabeth M Hodson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006763.pub3/information#CD006763-cr-0005">Tess E Cooper</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/information/en#CD006763-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 January 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006763.pub3">https://doi.org/10.1002/14651858.CD006763.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006763-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006763-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006763-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006763-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006763-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD006763-abs-0004">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD006763-abs-0014">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006763-abs-0001" lang="en"> <section id="CD006763-sec-0001"> <h3 class="title" id="CD006763-sec-0001">Background</h3> <p>There is strong evidence that our current consumption of salt is a major factor in the development of increased blood pressure (BP) and that a reduction in our salt intake lowers BP, whether BP levels are normal or raised initially. Effective control of BP in people with diabetes lowers the risk of strokes, heart attacks and heart failure and slows the progression of chronic kidney disease (CKD) in people with diabetes. This is an update of a review first published in 2010. </p> </section> <section id="CD006763-sec-0002"> <h3 class="title" id="CD006763-sec-0002">Objectives</h3> <p>To evaluate the effect of altered salt intake on BP and markers of cardiovascular disease and of CKD in people with diabetes. </p> </section> <section id="CD006763-sec-0003"> <h3 class="title" id="CD006763-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies up to 31 March 2022 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register were identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. </p> </section> <section id="CD006763-sec-0004"> <h3 class="title" id="CD006763-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of altered salt intake in individuals with type 1 and type 2 diabetes. Studies were included when there was a difference between low and high sodium intakes of at least 34 mmol/day. </p> </section> <section id="CD006763-sec-0005"> <h3 class="title" id="CD006763-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed studies and resolved differences by discussion. We calculated mean effect sizes as mean difference (MD) and 95% confidence intervals (CI) using the random‐effects model. Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. </p> </section> <section id="CD006763-sec-0006"> <h3 class="title" id="CD006763-sec-0006">Main results</h3> <p>Thirteen RCTs (313 participants), including 21 comparisons (studies), met our inclusion criteria. One RCT (two studies) was added to this review update. Participants included 99 individuals with type 1 diabetes and 214 individuals with type 2 diabetes. Two RCTs (four studies) included some participants with reduced overall kidney function. The remaining studies either reported that participants with reduced glomerular filtration rate (GFR) were excluded from the study or only included participants with microalbuminuria and normal GFR. Five studies used a parallel study design, and 16 used a cross‐over design. Studies were at high risk of bias for most criteria. Random sequence generation and allocation concealment were adequate in only three and two studies, respectively. One study was at low risk of bias for blinding of participants and outcome assessment, but no studies were at low risk for selective reporting. Twelve studies reported non‐commercial funding sources, three reported conflicts of interest, and eight reported adequate washout between interventions in cross‐over studies. </p> <p>The median net reduction in 24‐hour urine sodium excretion (24‐hour UNa) in seven long‐term studies (treatment duration four to 12 weeks) was 76 mmol (range 51 to 124 mmol), and in 10 short‐term studies (treatment duration five to seven days) was 187 mmol (range 86 to 337 mmol). Data were only available graphically in four studies. In long‐term studies, reduced sodium intake may lower systolic BP (SBP) by 6.15 mm Hg (7 studies: 95% CI ‐9.27 to ‐3.03; I² = 12%), diastolic BP (DBP) by 3.41 mm Hg (7 studies: 95% CI ‐5.56 to ‐1.27; I² = 41%) and mean arterial pressure (MAP) by 4.60 mm Hg (4 studies: 95% CI ‐7.26 to ‐1.94; I² = 28%). In short‐term studies, low sodium intake may reduce SBP by 8.43 mm Hg (5 studies: 95% CI ‐14.37 to ‐2.48; I² = 88%), DBP by 2.95 mm Hg (5 studies: 95% CI ‐4.96 to ‐0.94; I² = 70%) and MAP by 2.37 mm Hg (9 studies: 95% CI ‐4.75 to ‐0.01; I² = 65%). There was considerable heterogeneity in most analyses but particularly among short‐term studies. All analyses were considered to be of low certainty evidence. </p> <p>SBP, DBP and MAP reductions may not differ between hypertensive and normotensive participants or between individuals with type 1 or type 2 diabetes. In hypertensive participants, SBP, DBP and MAP may be reduced by 6.45, 3.15 and 4.88 mm Hg, respectively, while in normotensive participants, they may be reduced by 8.43, 2.95 and 2.15 mm Hg, respectively (all low certainty evidence). SBP, DBP and MAP may be reduced by 7.35, 3.04 and 4.30 mm Hg, respectively, in participants with type 2 diabetes and by 7.35, 3.20, and 0.08 mm Hg, respectively, in participants with type 1 diabetes (all low certainty evidence). </p> <p>Eight studies provided measures of urinary protein excretion before and after salt restriction; four reported a reduction in urinary albumin excretion with salt restriction. Pooled analyses showed no changes in GFR (12 studies: MD ‐1.87 mL/min/1.73 m², 95% CI ‐5.05 to 1.31; I² = 32%) or HbA1c (6 studies: MD ‐0.62, 95% CI ‐1.49 to 0.26; I² = 95%) with salt restriction (low certainty evidence). Body weight was reduced in studies lasting one to two weeks but not in studies lasting for longer periods (low certainty evidence). Adverse effects were reported in only one study; 11% and 21% developed postural hypotension on the low‐salt diet and the low‐salt diet combined with hydrochlorothiazide, respectively. </p> </section> <section id="CD006763-sec-0007"> <h3 class="title" id="CD006763-sec-0007">Authors' conclusions</h3> <p>This systematic review shows an important reduction in SBP and DBP in people with diabetes with normal GFR during short periods of salt restriction, similar to that obtained with single drug therapy for hypertension. These data support the international recommendations that people with diabetes with or without hypertension or evidence of kidney disease should reduce salt intake to less than 5 g/day (2 g sodium). </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006763-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006763-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD006763-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD006763-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006763-abs-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006763-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD006763-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/id#CD006763-abs-0019">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ja#CD006763-abs-0016">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD006763-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006763-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/nl#CD006763-abs-0020">Nederlands</a> </li> <li class="section-language"> <a class="" href="full/pt#CD006763-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD006763-abs-0015">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD006763-abs-0013">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006763-abs-0002" lang="en"> <h3>Does reducing your salt intake help to prevent and treat chronic kidney disease in people with diabetes? </h3> <p><b>What is the issue?</b> </p> <p>There is strong evidence that we all eat too much salt, which increases our risk of high blood pressure (BP). This is particularly important in people with diabetes as diabetes increases the risk of stroke, heart attack and kidney failure, and also having high BP will further increase these risks. Reducing salt intake could help by reducing BP and thus reducing the risk of heart attacks and of worsening kidney function. </p> <p><b>What did we do?</b> </p> <p>We searched the Cochrane Kidney and Transplant Register of Studies up to 31 March 2022 for randomised controlled trials which compared low and high levels of salt intake in people with diabetes. We calculated the average level of reduction in systolic BP (the "top" level of BP measured) and in diastolic BP (the "bottom" level of BP measured) in diabetics when they received a high salt diet and when they received a low salt diet. We also looked at whether the amount of protein in the urine (a marker of kidney damage) was reduced in diabetics receiving a low salt diet. </p> <p><b>What did we find?</b> </p> <p>We found 13 studies, including 313 people with type 1 or 2 diabetes. We found that reducing salt intake by an average of 5 g/day lowered BP, with systolic BP reduced by 7 mm of mercury (Hg) and diastolic BP reduced by 3 mm Hg. We found that the amount of protein in the urine was reduced in four of the eight studies that reported this outcome. Only one study reported side effects with low BP when standing up with low salt diets reported in a quarter of the participants. </p> <p><b>Conclusions</b> </p> <p>Lowering dietary salt intake to the recommended levels of 5 g/day or less would benefit people with diabetes by lowering BP by similar amounts to a single BP medication. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006763-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006763-sec-0088"></div> <h3 class="title" id="CD006763-sec-0089">Implications for practice</h3> <section id="CD006763-sec-0089"> <p>This updated systematic review confirms previous findings that salt reduction reduces BP in people with type 1 and type 2 diabetes and can increase pharmacological interventions' efficacy in achieving strict BP control.  These findings, in conjunction with other evidence relating salt intake to BP and albuminuria in hypertensive and normotensive people as well as in people with CKD, suggest that reducing salt intake in people with diabetes to the amounts recommended in public health guidelines for the general population may improve outcomes for people with diabetes. </p> </section> <h3 class="title" id="CD006763-sec-0090">Implications for research</h3> <section id="CD006763-sec-0090"> <p>The studies included in this review were of short duration, involved large changes in dietary salt intake and required frequent measurements of urinary sodium excretion. These studies demonstrated that short‐term reductions in salt intake result in important reductions in SBP, DBP and MAP in people with diabetes with normal GFR with or without microalbuminuria. However, these short‐term studies cannot assess patient‐level outcomes, including CVD and CKD. Assessing such patient‐level outcomes requires larger and longer‐term studies of reduction in salt intake. A recent study of Chinese people with hypertension and previous strokes (<a href="./references#CD006763-bbs2-0059" title="NealB , WuY , FengX , ZhangR , ZhangY , ShiJ , et al. Effect of salt substitution on cardiovascular events and death. New England Journal of Medicine2021;385(12):1067-77. [MEDLINE: 34459569]">Neal 2021</a>) has demonstrated that a longer‐term reduction in sodium intake with a reduction in cardiovascular and cerebral outcomes could be achieved using salt supplements (75% sodium chloride and 25% potassium chloride) to reduce sodium intake. Similar studies could be considered in people with diabetes without reduced GFR since replacing sodium chloride with potassium chloride is potentially harmful in participants with reduced GFR. However, the opportunity to do such studies is limited now that many people with type 2 diabetes are managed with SGLT2 inhibitors, increasing sodium excretion. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006763-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006763-sec-0008"></div> <div class="table" id="CD006763-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Reduced salt intake versus usual or high salt intake for preventing diabetic kidney disease and its progression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Reduced salt intake versus usual or high salt intake for preventing diabetic kidney disease and its progression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with diabetes with or without CKD </p> <p><b>Setting:</b> inpatients and outpatients<br/><b>Intervention:</b> reduced salt intake<br/><b>Comparison:</b> usual or high salt intake </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with usual or high salt intake</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with reduced salt intake</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systolic BP: long‐term studies</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean systolic BP was 6.15 mm Hg lower with a reduced salt intake (9.27 lower to 3.03 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systolic BP: short‐term studies</p> <p>Duration: 1 week</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean systolic BP was 8.43 mm Hg lower with a reduced salt intake (9.6 lower to 5.81 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diastolic BP: long‐term studies</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean diastolic BP was 3.41 mm Hg lower with a reduced salt intake (5.56 lower to 1.27 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diastolic BP: short‐term studies</p> <p>Duration: 1 week</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean diastolic BP was 2.95 mm Hg lower with a reduced salt intake (4.96 lower to 0.94 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MAP: all studies</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean MAP was 3.01 mm Hg lower with a reduced salt intake (4.95 lower to 1.07 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>421 (13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFF: all studies</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean GFR was 1.78 mL/min/1.73 m² lower<br/>with a reduced salt intake (4.21 lower to 0.65 higher) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>392 (12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body weight: all studies</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean body weight was 1.21 kg lower with a reduced salt intake (1.73 lower to 0.68 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>454 (12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/><br/><b>CKD:</b> Chronic kidney disease; <b>CI:</b> Confidence interval; <b>RCT:</b> Randomised controlled trial; <b>BP:</b> Blood pressure; <b>MD:</b> Mean difference; <b>MAP:</b> Mean arterial pressure; <b>GFR:</b> Glomerular filtration rate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Heterogeneity between studies </p> <p><sup>2</sup> High or unclear risk of bias for allocation concealment and blinding due to study design (cross‐over studies) with small numbers of enrolled participants </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006763-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Net change in blood pressure in hypertensive and normotensive participants with a reduced salt intake versus usual or high salt intake for preventing diabetic kidney disease and its progression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Net change in BP in hypertensive and normotensive participants with a reduced salt intake versus usual or high salt intake for preventing diabetic kidney disease and its progression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with diabetes with or without CKD<br/><b>Setting:</b> inpatients and outpatients<br/><b>Intervention:</b> reduced salt intake<br/><b>Comparison:</b> usual or high salt intake </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with usual or high salt intake</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with reduced salt intake</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Systolic BP</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean systolic BP in <b>hypertensive</b> patients was 6.45 mm Hg lower with a reduced salt intake (11.69 lower to 3.61 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean systolic BP in <b>normotensive</b> patients was 8.43 mm Hg lower with a reduced salt intake (9.6 lower to 5.81 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diastolic BP</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean diastolic BP in <b>hypertensive</b> patients was 3.15 mm Hg lower with a reduced salt intake (6.49 lower to 0.18 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean diastolic BP in <b>normotensive</b> patients was 2.95 mm Hg lower with a reduced salt intake (4.11 lower to 2 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MAP</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean MAP in <b>hypertensive</b> patients was 4.88 mm Hg lower with a reduced salt intake (10.39 lower to 0.63 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The MAP in <b>normotensive</b> patients was 2.15 mm Hg lower with a reduced salt intake (4.56 lower to 0.26 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BP:</b> Blood pressure; <b>CKD:</b> Chronic kidney disease; <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>MAP:</b> Mean arterial pressure </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Heterogeneity between studies </p> <p><sup>2</sup> High or unclear risk of bias for allocation concealment and blinding due to study design (cross‐over studies) with small numbers of enrolled participants </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006763-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Net change in blood pressure in participants with type 1 or type 2 diabetes with a reduced salt diet versus usual or high salt intake for preventing diabetic kidney disease and its progression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Net change in BP in participants with type 1 and type 2 diabetes with a reduced salt intake versus usual or high salt intake for preventing diabetic kidney disease and its progression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with diabetes with or without CKD<br/><b>Setting:</b> inpatients and outpatients<br/><b>Intervention:</b> reduced salt intake<br/><b>Comparison:</b> usual or high salt intake </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with usual or high salt intake</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with reduced salt intake</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Systolic BP</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean systolic BP in patients with <b>type 1 diabetes</b> was 7.35 mm Hg lower with a reduced salt intake (14.49 lower to 0.21 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean systolic BP in patients with <b>type 2 diabetes</b> was 7.35 mm Hg lower with a reduced salt intake (10.32 lower to 4.38 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diastolic BP:</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean diastolic BP in patients with <b>type 1 diabetes</b> was 3.20 mm Hg lower with a reduced salt intake (5.16 lower to 1.23 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean diastolic BP in patients with <b>type 2 diabetes</b> was 3.04 mm Hg lower with a reduced salt intake (5.20 lower to 0.89 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MAP</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean MAP in patients with <b>type 1 diabetes</b> was 0.08 mm Hg higher with a reduced salt intake (1.92 lower to 2.08 higher) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean MAP in patients with <b>type 2 diabetes</b> was 4.03 mm Hg lower with a reduced salt intake (6.54 lower to 2.05 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>359 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BP:</b> Blood pressure; <b>CKD:</b> Chronic kidney disease; <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>MAP:</b> Mean arterial pressure </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Heterogeneity between studies </p> <p><sup>2</sup> High or unclear risk of bias for allocation concealment and blinding due to study design (cross‐over studies) with small numbers of enrolled participants </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006763-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006763-sec-0009"></div> <section id="CD006763-sec-0010"> <h3 class="title" id="CD006763-sec-0010">Description of the condition</h3> <p>Approximately 75% of cardiovascular disease (CVD) in people with diabetes can be attributed to raised blood pressure (BP), and it is the largest direct cause of death due to stroke, heart attack and heart failure in people with diabetes (<a href="./references#CD006763-bbs2-0035" title="AdlerA , StrattonI , NeilH , YudkinJ , MatthewsD , CullC , et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ2000;321(7258):412-9. [MEDLINE: 10938049]">Adler 2000</a>; <a href="./references#CD006763-bbs2-0058" title="MozaffarianD , FahimiS , SinghGM , MichaR , KhatibzadehS , EngellRE , et al. Global sodium consumption and death from cardiovascular causes. New England Journal of Medicine2014;371(7):624-34. [MEDLINE: 25119608]">Mozaffarian 2014</a>; <a href="./references#CD006763-bbs2-0066" title="SowersJR , EpsteinM , FrohlichED . Diabetes, hypertension, and cardiovascular disease: an update [Erratum in: Hypertension 2001 May;37(5):1350]. Hypertension2001;37(4):1053-9. [MEDLINE: 11304502]">Sowers 2001</a>; <a href="./references#CD006763-bbs2-0067" title="StrainWD , PaldániusPM . Diabetes, cardiovascular disease and the microcirculation [Erratum in: Cardiovasc Diabetol. 2021 Jun 11;20(1):120]. Cardiovascular Diabetology2018;17(1):57. [MEDLINE: 29669543]">Strain 2018</a>). Chronic kidney disease (CKD) associated with diabetes is responsible for the largest group on dialysis programmes, with a significant burden on healthcare resources (<a href="./references#CD006763-bbs2-0046" title="HarveyJN . Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes. Current Opinions in Nephrology &amp; Hypertension2003;12:317-22. [MEDLINE: 12698072]">Harvey 2003</a>). Lowering BP reduces the progression of CKD in people with diabetes, and diabetic patients with BP less than 130/80 mm Hg have the same reduction in glomerular filtration rate (GFR) due to age as healthy individuals (<a href="./references#CD006763-bbs2-0042" title="GiuntiS , BaritD , CooperM . Mechanisms of diabetic nephropathy: role of hypertension. Hypertension2006;48(4):519-26. [MEDLINE: 16952978]">Giunti 2006</a>; <a href="./references#CD006763-bbs2-0063" title="SchrierRW , EstacioRO , EslerA , MehlerP . Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney International2002;61(3):1086-97. [MEDLINE: 11849464]">Schrier 2002</a>). </p> </section> <section id="CD006763-sec-0011"> <h3 class="title" id="CD006763-sec-0011">Description of the intervention</h3> <p>In an analysis for the Global Burden of Disease Study (<a href="./references#CD006763-bbs2-0041" title="GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet2019;393(10184):1958-72. [MEDLINE: 30954305]">GBD 2017</a>), a high salt intake was determined to be one of the main factors leading to increased death and morbidity among people worldwide due largely to CVD. Reducing salt intake reduces systolic BP (SBP) and diastolic BP (DBP) in adults and children (<a href="./references#CD006763-bbs2-0069" title="World Health Organization. Guideline: Sodium Intake for Adults and Children, 2012. Available at: https://www.who.int/publications/i/item/97892415048362012.">WHO 2012</a>). Therefore, WHO recommends a reduction in salt intake to below 5 g/day (&lt; 2 g/day sodium) in adults to reduce BP and the risk of CVD, stroke and coronary heart disease (<a href="./references#CD006763-bbs2-0069" title="World Health Organization. Guideline: Sodium Intake for Adults and Children, 2012. Available at: https://www.who.int/publications/i/item/97892415048362012.">WHO 2012</a>). In agreement with the WHO, the KDIGO guidelines (<a href="./references#CD006763-bbs2-0054" title="Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International2020;98(45):S1-115. [MEDLINE: 32998798]">KDIGO 2020</a>) on diabetes management in CKD recommend salt intake should be below 5 g/day (&lt; 2 g of sodium) in people with diabetes and CKD to potentiate the suppression of the renin‐angiotensin system (RAS) by angiotensin‐converting enzyme inhibitors (ACEi) or angiotensin receptors blockers (ARB). RAS blockade is considered essential to delay the progression of CKD in people with diabetes. However, cardiovascular and kidney protection by RAS blockade may not be complete. Therefore, additional strategies to improve the efficacy of RAS blockade, including dietary salt restriction, may be useful in people with diabetes to potentiate RAS blockade efficacy. </p> </section> <section id="CD006763-sec-0012"> <h3 class="title" id="CD006763-sec-0012">How the intervention might work</h3> <p>Diabetic patients differ from the nondiabetic population in having an increase in total body sodium, an increase in renal tubular sodium reabsorption, and an impaired ability to excrete a sodium load. These factors suggest that reducing dietary salt intake may play an important role in the management of hypertension in the diabetic population (<a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>). The activity of the sodium‐glucose co‐transporter increases proximal tubular reabsorption of sodium, and this reduces distal sodium delivery (<a href="./references#CD006763-bbs2-0070" title="WoodsLL , MizelleHL , HallJE . Control of renal hemodynamics in hyperglycemia: possible role of tubuloglomerular feedback. American Journal of Physiology1987;252(1 Pt 2):F65-73. [MEDLINE: 3812702]">Woods 1987</a>). Insulin directly increases distal tubular sodium reabsorption (<a href="./references#CD006763-bbs2-0039" title="DeFronzoRA . The effect of insulin on renal sodium metabolism. A review with clinical implications. Diabetologia1981;21(3):165-71. [MEDLINE: 7028550]">DeFronzo 1981</a>). Furthermore, increased angiotensin II in the tubular fluid activates sodium channels in the collecting duct (<a href="./references#CD006763-bbs2-0060" title="NishiyamaA , SethD , NavarL . Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension2002;39(1):129-34. [MEDLINE: 11799091]">Nishiyama 2002</a>). People with diabetes have a lower incidence of low renin state and a higher plasma renin activity on a high salt diet than volunteers. This lack of suppression of the RAS with a high salt diet may play a part in the development of hypertension (<a href="./references#CD006763-bbs2-0001" title="De'OliveiraJM , PriceDA , FisherND , AllanDR , McKnightJA , WilliamsGH , et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney International1997;52(3):771-7. [MEDLINE: 9291199]">De'Oliveira 1997</a>; <a href="./references#CD006763-bbs2-0061" title="PriceDA , De'OliveiraJM , FisherND , WilliamsGH , HollenbergNK . The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus. American Journal of Hypertension1999;12(4 Pt 1):348-55. [MEDLINE: 10232494]">Price 1999</a>) in people with diabetes. Lowering salt intake also reduces urinary protein excretion in several populations, and increased urinary protein excretion is an important marker of CKD and CVD in people with diabetes (<a href="./references#CD006763-bbs2-0036" title="AllenTJ , WaldronMJ , CasleyD , JerumsG , CooperME . Salt restriction reduces hyperfiltration, renal enlargement, and albuminuria in experimental diabetes. Diabetes1997;46(1):19-24. [MEDLINE: 8971091]">Allen 1997</a>; <a href="./references#CD006763-bbs2-0038" title="CianciarusoB , BellizziV , MinutoloR , TaveraA , CapuanoA , ConteG , et al. Salt intake and renal outcome in patients with progressive renal disease. Mineral &amp; Electrolyte Metabolism1998;24(4):296-301. [MEDLINE: 9554571]">Cianciaruso 1998</a>; <a href="./references#CD006763-bbs2-0049" title="HeFJ , MarciniakM , VisagieE , MarkanduND , AnandV , DaltonRN , et al. Effect of modest salt reduction on blood pressure, urinary albumin, and pulse wave velocity in white, black, and Asian mild hypertensives. Hypertension2009;54(3):482-8. [MEDLINE: 19620514]">He 2009a</a>; <a href="./references#CD006763-bbs2-0068" title="SwiftPA , MarkanduND , SagnellaGA , HeFJ , MacGregorGA . Modest salt reduction reduces blood pressure and urine protein excretion in black hypertensives: a randomized control trial. Hypertension2005;46(2):308-12. [MEDLINE: 15983240]">Swift 2005</a>). </p> </section> <section id="CD006763-sec-0013"> <h3 class="title" id="CD006763-sec-0013">Why it is important to do this review</h3> <p>There is strong evidence that our current consumption of salt is a major factor in increasing BP (<a href="./references#CD006763-bbs2-0041" title="GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet2019;393(10184):1958-72. [MEDLINE: 30954305]">GBD 2017</a>; <a href="./references#CD006763-bbs2-0050" title="HeF , MacGregorGA . A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. Journal of Human Hypertension2009;23(6):363-84. [MEDLINE: 19110538]">He 2009b</a>). Despite the high cardiovascular risk and theoretical reasons for increased salt sensitivity in people with diabetes, the current knowledge of the role of salt in regulating BP and its impact on people with diabetes is limited to small studies. Therefore, we carried out a systematic review of all studies where the salt intake was altered in people with diabetes. There are no standard criteria for high and low salt diets in people with diabetes. As with previous meta‐analyses of salt reduction, this review included studies where the difference in sodium intake between periods of high and low sodium intakes was at least 34 mmol/day (<a href="./references#CD006763-bbs2-0047" title="HeFJ , MacGregorGA . Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. Journal of Human Hypertension2002;16(11):761-70. [MEDLINE: 12444537]">He 2002</a>; <a href="./references#CD006763-bbs2-0048" title="HeFJ , MacGregorGA . How far should salt intake be reduced?Hypertension2003;42(6):1093-9. [MEDLINE: 14610100]">He 2003</a>; <a href="./references#CD006763-bbs2-0055" title="LawMR , FrostCD , WaldNJ . By how much does dietary salt reduction lower blood pressure? III - Analysis of data from trials of salt reduction [Erratum in: BMJ 1991 Apr 20;302(6782):939]. BMJ1991;302(6780):819-24. [MEDLINE: 1827353]">Law 1991</a>). This is an update of a review first published in 2010. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006763-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006763-sec-0014"></div> <p>We aimed to evaluate the effects of salt restriction on the prevention and progression of CKD in people with diabetes by studying the effects of changing salt intake on BP, urinary protein excretion and surrogate markers of CVD and CKD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006763-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006763-sec-0015"></div> <section id="CD006763-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006763-sec-0017"> <h4 class="title">Types of studies</h4> <p>For inclusion, studies needed to satisfy the following inclusion criteria. </p> <p> <ul id="CD006763-list-0001"> <li> <p>Randomised controlled trials (RCT) with random allocation to either a low or a high salt intake. </p> </li> <li> <p>Sodium intake was estimated by 24‐hour urinary sodium excretion (24‐hour UNa), and studies achieved a minimum difference in 24‐hour UNa of 34 mmol (i.e. 2 g salt/day)<b>.</b> The reduction in 24‐hour UNa was calculated as UNa (high) ‐ UNa (low) in cross‐over studies and was calculated as (UNa (high) ‐ UNa (low)) low salt group ‐ (UNa (high) ‐ UNa (low)) control group in parallel studies. For cross‐over studies, UNa (low) was the 24‐hour UNa at the end of the reduced salt period, and the UNa (high) was the 24‐hour UNa at the end of the high salt period. For parallel studies, UNa (high) and UNa (low) were the 24‐hour UNa measurements at baseline and at the end of the intervention for each group. </p> </li> <li> <p>Studies where concomitant interventions, such as antihypertensive medication or other dietary modifications, were used during the study period were included providing that these interventions were constant throughout the low and high salt period. </p> </li> </ul> </p> </section> <section id="CD006763-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included all RCTs of adults (18 years or older) with type 1 or type 2 diabetes mellitus, irrespective of ethnicity or gender. We excluded studies of children and pregnant women. </p> </section> <section id="CD006763-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies where a low salt intake was compared to a high salt intake with a minimum difference in 24‐hour UNa, as described above. </p> </section> <section id="CD006763-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>The updated primary and secondary outcomes aimed to cover all clinically relevant and critical outcomes according to the recent KDIGO guidelines (<a href="./references#CD006763-bbs2-0054" title="Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International2020;98(45):S1-115. [MEDLINE: 32998798]">KDIGO 2020</a>). </p> <section id="CD006763-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD006763-list-0002"> <li> <p>Net change in 24‐hour UNa</p> </li> <li> <p>Net change in 24‐hour BP (SBP, DBP, mean arterial pressure (MAP))</p> </li> <li> <p>Death (any cause)</p> </li> </ol> </p> </section> <section id="CD006763-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD006763-list-0003"> <li> <p>Functional kidney measurements: urinary albumin excretion (UAE), proteinuria, serum creatinine (SCr), creatinine clearance (CrCl), estimated (e) GFR, effective renal plasma flow (ERPF) </p> </li> <li> <p>Glycated haemoglobin (HbA1c), hypoglycaemia</p> </li> <li> <p>Body weight: body weight, body mass index (BMI)</p> </li> <li> <p>CVD events: stroke, heart failure, myocardial infarction</p> </li> <li> <p>Adverse events</p> </li> </ol> </p> </section> </section> </section> <section id="CD006763-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006763-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> up to 31 March 2022 through contact with the Information Specialist using search terms relevant to this review. The Register contains studies identified from the following sources: </p> <p> <ol id="CD006763-list-0004"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of kidney‐related journals and the proceedings of major kidney conferences</p> </li> <li> <p>Searching the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of search strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available on the Cochrane Kidney and Transplant website under <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">CKT Register of Studies</a>. </p> <p>See <a href="./appendices#CD006763-sec-0094">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD006763-sec-0025"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD006763-list-0005"> <li> <p>Reference lists of review articles and relevant studies.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD006763-sec-0026"> <h3 class="title" id="CD006763-sec-0026">Data collection and analysis</h3> <section id="CD006763-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently undertook an assessment of citations. We retrieved full articles if the initial assessment suggested that studies or reviews might include relevant data. We independently assessed abstracts and, if necessary, the full text to identify suitable studies. We resolved disagreements through discussion between the authors. </p> </section> <section id="CD006763-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We extracted data using standard data extraction forms. We recorded relevant data, including characteristics of the study, design (parallel or cross‐over), type of study (open, single‐blind, double‐blind), method of blinding, study duration and pre‐ and post‐intervention results. Where more than one publication of a study existed, we used the publication with the most complete data. </p> </section> <section id="CD006763-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were assessed independently by two authors using the risk of bias assessment tool (<a href="./references#CD006763-bbs2-0052" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>) (see <a href="./appendices#CD006763-sec-0095">Appendix 2</a>). </p> <p> <ul id="CD006763-list-0006"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD006763-list-0007"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at risk of bias?</p> </li> </ul> </p> </section> <section id="CD006763-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated treatment effects for each study. We calculated the mean difference (MD) for outcome measurements with 95% confidence intervals (CI). In cross‐over studies, we calculated the MD in outcomes as the difference between the end of the low salt period and the end of the high salt period. For parallel studies, we calculated the treatment effect as the difference between the two treatment groups in the change in outcomes from baseline. </p> </section> <section id="CD006763-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The majority of included studies were cross‐over studies, providing separate data for each treatment period's end. We calculated the treatment effect for cross‐over studies as the MD between the results at the end of the low salt period and those at the end of the high salt period.  </p> </section> <section id="CD006763-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the original authors when relevant data were not reported in the publication.</p> </section> <section id="CD006763-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We first assessed the heterogeneity by visual inspection of the forest plot. We then quantified statistical heterogeneity using the I² statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than sampling error (<a href="./references#CD006763-bbs2-0051" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [MEDLINE: 12958120]">Higgins 2003</a>). A guide to the interpretation of I² values was as follows. </p> <p> <ul id="CD006763-list-0008"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>The importance of the observed value of I² depends on the magnitude and direction of treatment effects and the strength of evidence for heterogeneity (e.g. P value from the Chi² test or a CI for I²) (<a href="./references#CD006763-bbs2-0052" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). </p> </section> <section id="CD006763-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to use funnel plots to assess the potential existence of small study bias (<a href="./references#CD006763-bbs2-0052" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). However, there were too few studies included in the review to allow assessment of reporting bias.  </p> </section> <section id="CD006763-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We pooled data using generic inverse variance with both fixed‐effect and random‐effects models to ensure the robustness of the model chosen and susceptibility to outliers. Data are presented using the random effects model. </p> </section> <section id="CD006763-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analyses were used to explore possible sources of heterogeneity.</p> <p> <ul id="CD006763-list-0009"> <li> <p>Long‐term (four to 12 weeks) versus short‐term studies (up to seven days)</p> </li> <li> <p>Studies of hypertensive versus normotensive participants</p> </li> <li> <p>Studies including type 1 versus type 2 diabetes participants</p> </li> </ul> </p> <p>Heterogeneity between studies may be related to the types of participants. Heterogeneity between studies could be related to variations in the degree of sodium reduction, the different durations of the studies, differences between parallel group and cross‐over designs and the presence or absence of a washout period between interventions in cross‐over studies.  </p> </section> <section id="CD006763-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We had planned to perform sensitivity analyses to explore the influence of the following factors on effect size. However, we could not undertake most of these analyses as outlined below. </p> <p> <ul id="CD006763-list-0010"> <li> <p>Repeating the analysis, excluding unpublished studies</p> </li> <li> <p>Repeating the analysis taking account of the risk of bias, as specified</p> </li> <li> <p>Repeating the analysis, excluding any very long or large studies, to establish how much they dominate the results. </p> </li> </ul> </p> </section> <section id="CD006763-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD006763-bbs2-0064" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. www.training.cochrane.org/handbook.">Schunemann 2022a</a>). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD006763-bbs2-0043" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">GRADE 2008</a>; <a href="./references#CD006763-bbs2-0044" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [MEDLINE: 21195583]">GRADE 2011</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of the within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, the precision of effect estimates and risk of publication bias (<a href="./references#CD006763-bbs2-0065" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schunemann 2022b</a>). We presented the following outcomes in the 'Summary of findings' tables: </p> <p> <ul id="CD006763-list-0011"> <li> <p>Net changes in SBP, DBP, MAP, GFR and weight with reduced dietary salt in all participants</p> </li> <li> <p>Net changes in SBP, DBP and MAP with reduced dietary salt in hypertensive and normotensive participants </p> </li> <li> <p>Net changes in SBP, DBP and MAP with reduced dietary salt in type 1 and type 2 diabetes participants. </p> </li> </ul> </p> <p>We had planned to include data on death and cardiovascular outcomes in the Summary of Findings Tables, but no data were available for these outcomes from included studies. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006763-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006763-sec-0039"></div> <section id="CD006763-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD006763-sec-0041"> <h4 class="title">Results of the search</h4> <p>The initial search in 2010 identified 914 citations, of which 72 reports were potentially eligible. After full‐text analysis, 13 RCTs (16 reports, 254 participants) were included, and 53 studies (56 reports) were excluded. </p> <p>For this 2022 update, two additional RCTs were identified, of which one was excluded (<a href="./references#CD006763-bbs2-0033" title="OyabuC , UshigomeE , OnoY , KobayashiA , HashimotoY , SakaiR , et al. Randomized controlled trial of simple salt reduction instructions by physician for patients with type 2 diabetes consuming excessive salt. International Journal of Environmental Research &amp; Public Health [Electronic Resource]2021;18(13):Article No: 6813. [MEDLINE: 34203155]UshigomeE , OyabuC , ShiraishiM , KitagawaN , KitaeA , IwaiK , et al. Evaluation of the efficacy of simplified nutritional instructions from physicians on dietary salt restriction for patients with type 2 diabetes mellitus consuming excessive salt: protocol for a randomized controlled trial. Trials [Electronic Resource]2019;20(1):761. [MEDLINE: 31870424]">Ushigome 2019</a>) and one was included (<a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>). <a href="./references#CD006763-bbs2-0030" title="PetrieJR , MorrisAD , MinamisawaK , HilditchTE , ElliottHL , SmallM , et al. Dietary sodium restriction impairs insulin sensitivity in noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology &amp; Metabolism1998;83(5):1552-7. [MEDLINE: 9589654]">Petrie 1998</a>, which was included in the 2010 review, was reviewed and was excluded from this update as frusemide was only given to the high salt intake group and would have increased sodium excretion. Therefore, for this update, we included 13 studies (20 reports) with 313 participants were included in this review (<a href="#CD006763-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD006763-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD006763-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD006763-sec-0042"> <h4 class="title">Included studies</h4> <p>To avoid confusion, we used the term "study" for each entry throughout this meta‐analysis because some RCTs had two or more comparisons and have been split and entered more than once for the purpose of the meta‐analyses. There were 21 separate studies from 13 RCTs with 313 included participants. </p> <p> <ul id="CD006763-list-0012"> <li> <p>One article presented two separate studies (one with a cross‐over design and the other with a parallel design); we entered the data for these as separate studies in this meta‐analysis (<a href="./references#CD006763-bbs2-0002" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_P 1989</a>; <a href="./references#CD006763-bbs2-0003" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_X 1989</a>). </p> </li> <li> <p>Six studies (113 participants) used parallel design (<a href="./references#CD006763-bbs2-0001" title="De'OliveiraJM , PriceDA , FisherND , AllanDR , McKnightJA , WilliamsGH , et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney International1997;52(3):771-7. [MEDLINE: 9291199]">De'Oliveira 1997</a>; <a href="./references#CD006763-bbs2-0002" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_P 1989</a>; <a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>; <a href="./references#CD006763-bbs2-0013" title="MillerJA . Renal responses to sodium restriction in patients with early diabetes mellitus. Journal of the American Society of Nephrology1997;8(5):749-55. [MEDLINE: 9176844]">Miller 1997</a>; <a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a>), and 15 studies (200 participants) used a cross‐over design. </p> </li> <li> <p>Seven studies (<a href="./references#CD006763-bbs2-0010" title="Lopes de FariaJB , FriedmanR , deCosmoS , DoddsRA , MorttonJJ , VibertiGC . Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake. Nephron1997;76(4):411-7. [MEDLINE: 9274838]">Lopes De Faria 1997</a>; <a href="./references#CD006763-bbs2-0011" title="LuikPT , HoogenbergK , Van Der KleijFG , BeusekampBJ , KerstensMN , De JongPE , et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. Diabetologia2002;45(4):535-41. [MEDLINE: 12032630]">Luik 2002</a>; <a href="./references#CD006763-bbs2-0012" title="MillerJA . Sympathetic vasoconstrictive responses to high- and low-sodium diets in diabetic and normal subjects. American Journal of Physiology1995;269(2 Pt 2):R380-8. [MEDLINE: 7653660]">Miller 1995</a>; <a href="./references#CD006763-bbs2-0013" title="MillerJA . Renal responses to sodium restriction in patients with early diabetes mellitus. Journal of the American Society of Nephrology1997;8(5):749-55. [MEDLINE: 9176844]">Miller 1997</a>; <a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a>; <a href="./references#CD006763-bbs2-0015" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Micro 1998</a>; <a href="./references#CD006763-bbs2-0016" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Normo 1998</a>) enrolled 99 participants with type 1 diabetes, while 14 studies enrolled 214 participants with type 2 diabetes. </p> </li> <li> <p>Four studies (<a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>; <a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>) included some participants with reduced overall kidney function. The remaining 17 studies either reported that participants with reduced GFR were excluded from the study or only included participants with microalbuminuria and normal GFR (<a href="./appendices#CD006763-sec-0096">Appendix 3</a>). </p> </li> <li> <p>Six studies enrolled participants with normal levels of albuminuria (<a href="./references#CD006763-bbs2-0002" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_P 1989</a>; <a href="./references#CD006763-bbs2-0003" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_X 1989</a>; <a href="./references#CD006763-bbs2-0010" title="Lopes de FariaJB , FriedmanR , deCosmoS , DoddsRA , MorttonJJ , VibertiGC . Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake. Nephron1997;76(4):411-7. [MEDLINE: 9274838]">Lopes De Faria 1997</a>; <a href="./references#CD006763-bbs2-0011" title="LuikPT , HoogenbergK , Van Der KleijFG , BeusekampBJ , KerstensMN , De JongPE , et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. Diabetologia2002;45(4):535-41. [MEDLINE: 12032630]">Luik 2002</a>; <a href="./references#CD006763-bbs2-0012" title="MillerJA . Sympathetic vasoconstrictive responses to high- and low-sodium diets in diabetic and normal subjects. American Journal of Physiology1995;269(2 Pt 2):R380-8. [MEDLINE: 7653660]">Miller 1995</a>; <a href="./references#CD006763-bbs2-0013" title="MillerJA . Renal responses to sodium restriction in patients with early diabetes mellitus. Journal of the American Society of Nephrology1997;8(5):749-55. [MEDLINE: 9176844]">Miller 1997</a>). Three studies included only participants with microalbuminuria (<a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>; <a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a>), and two studies included participants with micro‐ or macroalbuminuria (<a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>). Nine studies presented data separately for participants with normal levels of albuminuria or with albuminuria (<a href="./references#CD006763-bbs2-0006" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Micro 2001</a>; <a href="./references#CD006763-bbs2-0007" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Normo 2001</a>; <a href="./references#CD006763-bbs2-0015" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Micro 1998</a>; <a href="./references#CD006763-bbs2-0016" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Normo 1998</a>; <a href="./references#CD006763-bbs2-0017" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Micro 2004</a>; <a href="./references#CD006763-bbs2-0018" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Normo 2004</a>; <a href="./references#CD006763-bbs2-0019" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Adva Alb 1998</a>; <a href="./references#CD006763-bbs2-0020" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Micro 1998</a>; <a href="./references#CD006763-bbs2-0021" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Normo 1998</a>). </p> </li> <li> <p>Four studies compared salt reduction with normal salt intake in two groups of participants with type 2 diabetes and presented data for both categories separately. </p> <ul id="CD006763-list-0013"> <li> <p>Two studies (<a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>) compared salt restriction with normal salt intake in two groups, one receiving losartan and one receiving a placebo. </p> </li> <li> <p>Two studies (<a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>) compared salt restriction with normal salt intake in two groups, one receiving a placebo and one receiving hydrochlorothiazide, with all participants receiving maximal doses of lisinopril. </p> </li> </ul> </li> <li> <p>The duration ranged from four to 12 weeks in seven studies and were considered to be long‐term studies (<a href="./references#CD006763-bbs2-0002" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_P 1989</a>; <a href="./references#CD006763-bbs2-0003" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_X 1989</a>; <a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>; <a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>; <a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a>). The remaining 14 studies were short‐term studies with treatment durations of less than two weeks. </p> </li> <li> <p>Six studies included 102 participants with high BP (&gt; 140/90 mm Hg) (<a href="./references#CD006763-bbs2-0001" title="De'OliveiraJM , PriceDA , FisherND , AllanDR , McKnightJA , WilliamsGH , et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney International1997;52(3):771-7. [MEDLINE: 9291199]">De'Oliveira 1997</a>; <a href="./references#CD006763-bbs2-0002" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_P 1989</a>; <a href="./references#CD006763-bbs2-0003" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_X 1989</a>; <a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>; <a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a>), and 13 studies included 166 participants with normal BP (&lt; 140/90 mm Hg). Two studies (45 participants) included participants with BP ≤ 180/110 mm Hg (<a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>). </p> </li> <li> <p>UNa excretion was only available graphically in four studies (<a href="./references#CD006763-bbs2-0006" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Micro 2001</a>; <a href="./references#CD006763-bbs2-0007" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Normo 2001</a>; <a href="./references#CD006763-bbs2-0017" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Micro 2004</a>; <a href="./references#CD006763-bbs2-0018" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Normo 2004</a>). </p> </li> <li> <p>The age of participants ranged from 18 to 65 years.</p> </li> </ul> </p> <p>We have summarised the studies' characteristics in the review in <a href="./appendices#CD006763-sec-0096">Appendix 3</a>. </p> <section id="CD006763-sec-0043"> <h5 class="title">Outcome reporting</h5> <p>All studies reported BP measurements and 24‐hour UNa. There was much variability in reporting of measurements of kidney function and UAE. Studies used different isotopes to measure GFR and other haemodynamic measurements. UAE was reported in ways that could not be entered into a pooled analysis: two studies reported data as geometric mean and percentage change (<a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>); two studies reported data as mean albumin excretion and as albumin:creatinine ratios (<a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>); one study reported data as a change in 24‐hour albumin excretion (<a href="./references#CD006763-bbs2-0011" title="LuikPT , HoogenbergK , Van Der KleijFG , BeusekampBJ , KerstensMN , De JongPE , et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. Diabetologia2002;45(4):535-41. [MEDLINE: 12032630]">Luik 2002</a>); one study reported the mean level and range of urinary albumin (<a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a>); and two studies presented data as the median and interquartile range of albumin excretion (<a href="./references#CD006763-bbs2-0017" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Micro 2004</a>; <a href="./references#CD006763-bbs2-0018" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Normo 2004</a>). We have summarised the outcomes reported in each study in <a href="./appendices#CD006763-sec-0097">Appendix 4</a>. </p> </section> </section> <section id="CD006763-sec-0044"> <h4 class="title">Excluded studies</h4> <p>Fourteen studies in people with diabetes were excluded. Six studies were excluded because they studied multiple interventions (<a href="./references#CD006763-bbs2-0022" title="ShikataK , HanedaM , KoyaD , SuzukiY , TominoY , YamadaK , et al. Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): rationale and study design. Diabetes Research &amp; Clinical Practice2010;87(2):228-32. [MEDLINE: 19889469]ShikataK , HanedaM , NinomiyaT , KoyaD , SuzukiY , SuzukiD , et al. Randomized trial of an intensified, multifactorial intervention in patients with advanced-stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan). Journal of Diabetes Investigation2021;12(2):207-16. [MEDLINE: 32597548]">DNETT Japan 2010</a>; <a href="./references#CD006763-bbs2-0023" title="DodsonPM , PacyPJ , BalP , KubickiAJ , FletcherRF , TaylorKG . A controlled trial of a high fibre, low fat and low sodium diet for mild hypertension in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia1984;27(5):522-6. [MEDLINE: 6096193]">Dodson 1984</a>; <a href="./references#CD006763-bbs2-0024" title="ChenAX , MoranJL , LibiantoR , BaqarS , O'CallaghanC , MacIsaacRJ , et al. Effect of angiotensin II receptor blocker and salt supplementation on short-term blood pressure variability in type 2 diabetes. Journal of Human Hypertension2020;34(2):143-50. [MEDLINE: 31501493]EkinciEI , ThomasG , ThomasD , JohnsonC , MacisaacRJ , HoulihanCA , et al. Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake. Diabetes Care2009;32(8):1398-403. [MEDLINE: 19549737]">Ekinci 2009</a>; <a href="./references#CD006763-bbs2-0025" title="GilleranG , O'LearyM , BartlettWA , VinallH , JonesAF , DodsonPM . Effects of dietary sodium substitution with potassium and magnesium in hypertensive type II diabetics: a randomised blind controlled parallel study. Journal of Human Hypertension1996;10(8):517-21. [MEDLINE: 8895035]">Gilleran 1996</a>; <a href="./references#CD006763-bbs2-0026" title="HelouN , TalhouedecD , ShahaM , ZanchiA . The impact of a multidisciplinary self-care management program on quality of life, self-care, adherence to anti-hypertensive therapy, glycemic control, and renal function in diabetic kidney disease: a cross-over study protocol. BMC Nephrology2016;17(1):88. [MEDLINE: 27430216]HelouN , TalhouedecD , Zumstein-ShahaM , ZanchiA . A multidisciplinary approach for improving quality of life and self-management in diabetic kidney disease: a crossover study. Journal of Clinical Medicine2020;9(7):Article No: 2160. [MEDLINE: 32650548]">Helou 2016</a>; <a href="./references#CD006763-bbs2-0027" title="SevickMA , WoolfK , MattooA , KatzSD , LiH , St-JulesDE , et al. The Healthy Hearts and Kidneys (HHK) study: Design of a 2x2 RCT of technology-supported self-monitoring and social cognitive theory-based counseling to engage overweight people with diabetes and chronic kidney disease in multiple lifestyle changes. Contemporary Clinical Trials2018;64:265-73. [MEDLINE: 28867396]">HHK 2018</a>) rather than altered salt intake. Three studies included some participants without diabetes, and the data for participants with or without diabetes could not be separated (<a href="./references#CD006763-bbs2-0029" title="CampbellKL , JohnsonDW , BauerJD , HawleyCM , IsbelNM , StowasserM , et al. A randomized trial of sodium-restriction on kidney function, fluid volume and adipokines in CKD patients. BMC Nephrology2014;15:Article No: 57. [MEDLINE: 24708818]Low Salt CKD Study Investigators. Individual patient data (as supplied 24 May 2019). Data on file. McMahonE , BauerJ , HawleyC , IsbelN , StowasserM , JohnsonD , et al. Effect of sodium restriction on blood pressure, fluid status and proteinuria in CKD patients: results of a randomised crossover trial and 6-month follow-up [abstract no: 004]. Nephrology2013;18(Suppl 1):15-6. [EMBASE: 71356987]McMahonEJ , BauerJD , HawleyCM , IsbelNM , StowasserM , JohnsonDW , et al. A randomized trial of dietary sodium restriction in CKD. Journal of the American Society of Nephrology2013;24(12):2096-103. [MEDLINE: 24204003]McMahonEJ , BauerJD , HawleyCM , IsbelNM , StowasserM , JohnsonDW , et al. The effect of lowering salt intake on ambulatory blood pressure to reduce cardiovascular risk in chronic kidney disease (LowSALT CKD study): protocol of a randomized trial. BMC Nephrology2012;13:Article No: 137. [MEDLINE: 23082956]">LowSALT CKD 2012</a>; <a href="./references#CD006763-bbs2-0032" title="SucklingR , HeF , MarkanduN , MacGregorG . Modest salt reduction in impaired glucose tolerance and type 2 diabetes lowers blood pressure and urinary albumin excretion [abstract no: Su139]. NDT Plus2010;3(Suppl 3):iii349. [EMBASE: 70484357]SucklingR , HeF , MarkanduN , MacGregorG . Modest salt reduction lowers blood pressure and urinary albumin excretion in impaired glucose tolerance and type 2 diabetes [abstract no: SA.01]. Journal of Hypertension2010;28(Suppl A):e219. [EMBASE: 70214893]SucklingRJ , HeF , MarkanduN , MacGregorG . Modest reduction in salt intake lowers blood pressure and urinary albumin excretion in individuals with impaired glucose tolerance and type II diabetes [abstract no: PE.02]. Journal of Human Hypertension2010;24(10):708. [EMBASE: 70273931]SucklingRJ , HeFJ , MarkanduND , MacGregorGA . Modest salt reduction lowers blood pressure and albumin excretion in impaired glucose tolerance and type 2 diabetes mellitus: a randomized double-blind trial. Hypertension2016;67(6):1189-95. [MEDLINE: 27160199]">Suckling 2016</a>; <a href="./references#CD006763-bbs2-0034" title="De BorstMH , KeyzerCA , vanBredaF , VervloetMG , LavermanGD , HemmelderMH , et al. Vitamin D receptor activation and dietary sodium restriction to reduce residual albuminuria in chronic kidney disease [abstract no: SA-PO1106]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B7. deJongMA , KeyzerCA , vanBredaF , VervloetMG , LavermanGD , HemmelderMH , et al. Baseline 25-hydroxyvitamin D level and the anti-albuminuric response to vitamin D receptor activation in patients with chronic kidney disease [abstract no: TH-PO515]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):210A-1A. deJongMA , KeyzerCA , vanBredaF , VervloetMG , NavisG , BakkerSJL , et al. Effect of vitamin D receptor activation and sodium restriction on calcification propensity and fibroblast growth factor 23: the Virtue-CKD trial [abstract no: TH-PO516]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):211A. KeyzerCA , deJongMA , Fenna van BredaG , VervloetMG , LavermanGD , HemmelderM , et al. Vitamin D receptor activator and dietary sodium restriction to reduce residual urinary albumin excretion in chronic kidney disease (ViRTUE study): rationale and study protocol. Nephrology Dialysis Transplantation2016;31(7):1081-7. [MEDLINE: 25744274]KeyzerCA , vanBredaGF , VervloetMG , deJongMA , LavermanGD , HemmelderMH , et al. Effects of vitamin D receptor activation and dietary sodium restriction on residual albuminuria in CKD: the ViRTUE-CKD trial. Journal of the American Society of Nephrology2016;28(4):1296-305. [MEDLINE: 27856633]">ViRTUE‐CKD 2016</a>). Two studies did not measure urinary sodium levels (<a href="./references#CD006763-bbs2-0028" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , TanakaS , FujiiS , et al. Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy. Kidney International - Supplement1997;52(63):S198-200. [MEDLINE: 9407458]">Imanishi 1997</a>; <a href="./references#CD006763-bbs2-0033" title="OyabuC , UshigomeE , OnoY , KobayashiA , HashimotoY , SakaiR , et al. Randomized controlled trial of simple salt reduction instructions by physician for patients with type 2 diabetes consuming excessive salt. International Journal of Environmental Research &amp; Public Health [Electronic Resource]2021;18(13):Article No: 6813. [MEDLINE: 34203155]UshigomeE , OyabuC , ShiraishiM , KitagawaN , KitaeA , IwaiK , et al. Evaluation of the efficacy of simplified nutritional instructions from physicians on dietary salt restriction for patients with type 2 diabetes mellitus consuming excessive salt: protocol for a randomized controlled trial. Trials [Electronic Resource]2019;20(1):761. [MEDLINE: 31870424]">Ushigome 2019</a>). One study included in the initial review was excluded in this update because additional frusemide was given to the high‐salt group but not the low‐salt group (<a href="./references#CD006763-bbs2-0030" title="PetrieJR , MorrisAD , MinamisawaK , HilditchTE , ElliottHL , SmallM , et al. Dietary sodium restriction impairs insulin sensitivity in noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology &amp; Metabolism1998;83(5):1552-7. [MEDLINE: 9589654]">Petrie 1998</a>). <a href="./references#CD006763-bbs2-0031" title="ParvanovaA , TrilliniM , PodestaMA , IlievIP , RuggieroB , AbbateM , et al. Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. The Lancet Diabetes &amp; Endocrinology2018;6(1):27-40. [MEDLINE: 29104158]">PROCEED 2018</a> was excluded because the difference in 24‐hour UNa between high and low sodium intakes was less than 34 mmol/L. </p> </section> </section> <section id="CD006763-sec-0045"> <h3 class="title">Risk of bias in included studies</h3> <p>All included studies were small and of variable methodology resulting generally in high risk of bias (<a href="#CD006763-fig-0002">Figure 2</a>; <a href="#CD006763-fig-0003">Figure 3</a>) </p> <div class="figure" id="CD006763-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006763-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD006763-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006763-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD006763-sec-0046"> <h4 class="title">Allocation</h4> <section id="CD006763-sec-0047"> <h5 class="title">Random sequence generation</h5> <p>Three studies were at low risk of bias for sequence generation. Low risk of bias was judged when the method of randomisation was reported as random number allocation in <a href="./references#CD006763-bbs2-0011" title="LuikPT , HoogenbergK , Van Der KleijFG , BeusekampBJ , KerstensMN , De JongPE , et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. Diabetologia2002;45(4):535-41. [MEDLINE: 12032630]">Luik 2002</a> and by computer randomisation in blocks of two (<a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>). Sixteen studies were judged to be at unclear risk of bias as they provided no details about how the methods of randomisation were performed. Two studies were judged as having a high risk of bias because the dietician randomised the patients upon enrolment (<a href="./references#CD006763-bbs2-0012" title="MillerJA . Sympathetic vasoconstrictive responses to high- and low-sodium diets in diabetic and normal subjects. American Journal of Physiology1995;269(2 Pt 2):R380-8. [MEDLINE: 7653660]">Miller 1995</a>; <a href="./references#CD006763-bbs2-0013" title="MillerJA . Renal responses to sodium restriction in patients with early diabetes mellitus. Journal of the American Society of Nephrology1997;8(5):749-55. [MEDLINE: 9176844]">Miller 1997</a>). </p> </section> <section id="CD006763-sec-0048"> <h5 class="title">Allocation concealment</h5> <p>Two studies provided a description of allocation concealment by reporting that the randomisation code remained a secret during the entire trial and was judged to be at low risk of bias (<a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>). One study was judged to be a high risk of bias (<a href="./references#CD006763-bbs2-0010" title="Lopes de FariaJB , FriedmanR , deCosmoS , DoddsRA , MorttonJJ , VibertiGC . Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake. Nephron1997;76(4):411-7. [MEDLINE: 9274838]">Lopes De Faria 1997</a>). The remaining 18 studies did not provide information about allocation concealment and were judged to have an unclear risk of bias. </p> </section> </section> <section id="CD006763-sec-0049"> <h4 class="title">Blinding</h4> <section id="CD006763-sec-0050"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>Only <a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a> adequately described the methods used for double‐blinding of both the patients and investigators and was judged to be at low risk of bias. </p> <p>Three studies were stated to be double‐blind trials but failed to provide any further details about how the participants or personnel were kept blind to treatments, and so were judged to be an unclear risk of bias (<a href="./references#CD006763-bbs2-0003" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_X 1989</a>; <a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>). </p> <p>The remaining 17 studies were unblinded, open‐label studies and judged to be at high risk of bias. In <a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a> and <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>, the dietary component was open‐label, but the hydrochlorothiazide and placebo were double‐blind, and for this reason, the study was judged at a high risk of bias. </p> </section> <section id="CD006763-sec-0051"> <h5 class="title">Blinding of outcome assessors (detection bias)</h5> <p>Only <a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a> adequately described the methods used to keep all investigators, and outcome assessors blind until the last patient had completed the study and was judged to be at low risk of bias. </p> <p><a href="./references#CD006763-bbs2-0012" title="MillerJA . Sympathetic vasoconstrictive responses to high- and low-sodium diets in diabetic and normal subjects. American Journal of Physiology1995;269(2 Pt 2):R380-8. [MEDLINE: 7653660]">Miller 1995</a> reported the investigators remained blind to the diets, but no further details were provided about how this was carried out, so this study was judged as at unclear risk of bias. </p> <p>The remaining 19 studies were either unblinded (<a href="./references#CD006763-bbs2-0001" title="De'OliveiraJM , PriceDA , FisherND , AllanDR , McKnightJA , WilliamsGH , et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney International1997;52(3):771-7. [MEDLINE: 9291199]">De'Oliveira 1997</a>; <a href="./references#CD006763-bbs2-0002" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_P 1989</a>; <a href="./references#CD006763-bbs2-0006" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Micro 2001</a>; <a href="./references#CD006763-bbs2-0007" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Normo 2001</a>; <a href="./references#CD006763-bbs2-0010" title="Lopes de FariaJB , FriedmanR , deCosmoS , DoddsRA , MorttonJJ , VibertiGC . Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake. Nephron1997;76(4):411-7. [MEDLINE: 9274838]">Lopes De Faria 1997</a>; <a href="./references#CD006763-bbs2-0011" title="LuikPT , HoogenbergK , Van Der KleijFG , BeusekampBJ , KerstensMN , De JongPE , et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. Diabetologia2002;45(4):535-41. [MEDLINE: 12032630]">Luik 2002</a>) or stated to be double‐blind studies but provided no information regarding the blinding of outcome assessors (<a href="./references#CD006763-bbs2-0003" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_X 1989</a>; <a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>; <a href="./references#CD006763-bbs2-0013" title="MillerJA . Renal responses to sodium restriction in patients with early diabetes mellitus. Journal of the American Society of Nephrology1997;8(5):749-55. [MEDLINE: 9176844]">Miller 1997</a>; <a href="./references#CD006763-bbs2-0015" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Micro 1998</a>; <a href="./references#CD006763-bbs2-0016" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Normo 1998</a>; <a href="./references#CD006763-bbs2-0017" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Micro 2004</a>; <a href="./references#CD006763-bbs2-0018" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Normo 2004</a>; <a href="./references#CD006763-bbs2-0019" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Adva Alb 1998</a>; <a href="./references#CD006763-bbs2-0020" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Micro 1998</a>; <a href="./references#CD006763-bbs2-0021" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Normo 1998</a>). In <a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a> and <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>, the dietary component was open‐label, but the hydrochlorothiazide and placebo were double‐blind, and for this reason, the study was judged at high risk of bias.<br/>  </p> </section> </section> <section id="CD006763-sec-0052"> <h4 class="title">Incomplete outcome data</h4> <p>In two studies, all participants were accounted for from the start to the end of the study, with only two participants withdrawing per study (attrition rate = 4%). Intention‐to‐treat (ITT) analysis was performed for the original participant samples, including those two withdrawals (ITT; N = 45), so the studies were judged to be low risk of bias (<a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>). </p> <p>In three studies, all participants were accounted for from the start to the end of the study. No participants dropped out. However, it was unclear whether ITT analysis was performed; therefore, the studies were judged to be at unclear risk of bias (<a href="./references#CD006763-bbs2-0019" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Adva Alb 1998</a>; <a href="./references#CD006763-bbs2-0020" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Micro 1998</a>; <a href="./references#CD006763-bbs2-0021" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Normo 1998</a>). </p> <p>In the remaining 16 studies, either withdrawals or data were not complete; study attrition was not clearly reported, or an ITT analysis was not reported or performed, and therefore the studies were judged to be at high risk of bias. </p> </section> <section id="CD006763-sec-0053"> <h4 class="title">Selective reporting</h4> <p>All 21 studies were judged to be at high risk of bias. In all studies, the outcomes planned in the methods were reported in the results. However, none of the studies had published protocols or trial registrations to provide evidence to show that reporting bias was not present. In four studies, the protocol was provided as supplementary materials. either online or in appendices. However, all were published at the same time as the article, which was considered insufficient, so they were judged to be at high risk of bias (<a href="./references#CD006763-bbs2-0006" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Micro 2001</a>; <a href="./references#CD006763-bbs2-0007" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Normo 2001</a>; <a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>). </p> </section> <section id="CD006763-sec-0054"> <h4 class="title">Other potential sources of bias</h4> <section id="CD006763-sec-0055"> <h5 class="title">Funding declaration</h5> <p>Seventeen studies declared their funding sources. Twelve were not industry funding and were judged to be at low risk of bias. Five declared funding from the pharmaceutical industry and were judged to be at high risk of bias (<a href="./references#CD006763-bbs2-0002" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_P 1989</a>; <a href="./references#CD006763-bbs2-0003" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_X 1989</a>; <a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>; <a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a>). The remaining four studies failed to declare any sources of funding and were judged to be at unclear risk of bias (<a href="./references#CD006763-bbs2-0010" title="Lopes de FariaJB , FriedmanR , deCosmoS , DoddsRA , MorttonJJ , VibertiGC . Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake. Nephron1997;76(4):411-7. [MEDLINE: 9274838]">Lopes De Faria 1997</a>; <a href="./references#CD006763-bbs2-0019" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Adva Alb 1998</a>; <a href="./references#CD006763-bbs2-0020" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Micro 1998</a>; <a href="./references#CD006763-bbs2-0021" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Normo 1998</a>). </p> </section> <section id="CD006763-sec-0056"> <h5 class="title">Conflicts of interest</h5> <p>Only three studies reported conflicts of interest, and all three declared no competing interests (<a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>; <a href="./references#CD006763-bbs2-0010" title="Lopes de FariaJB , FriedmanR , deCosmoS , DoddsRA , MorttonJJ , VibertiGC . Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake. Nephron1997;76(4):411-7. [MEDLINE: 9274838]">Lopes De Faria 1997</a>). Two studies were judged to be at high risk of bias (<a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>). The remaining 16 studies did not report any details about whether they had conflicts or not and were judged to be at unclear risk of bias. </p> </section> <section id="CD006763-sec-0057"> <h5 class="title">Other information</h5> <p>Eight studies were judged to be at low risk of other potential biases because they either did not require a washout period (parallel design) or a sufficient washout period of seven days or more was applied (<a href="./references#CD006763-bbs2-0001" title="De'OliveiraJM , PriceDA , FisherND , AllanDR , McKnightJA , WilliamsGH , et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney International1997;52(3):771-7. [MEDLINE: 9291199]">De'Oliveira 1997</a>; <a href="./references#CD006763-bbs2-0002" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_P 1989</a>; <a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>; <a href="./references#CD006763-bbs2-0010" title="Lopes de FariaJB , FriedmanR , deCosmoS , DoddsRA , MorttonJJ , VibertiGC . Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake. Nephron1997;76(4):411-7. [MEDLINE: 9274838]">Lopes De Faria 1997</a>; <a href="./references#CD006763-bbs2-0011" title="LuikPT , HoogenbergK , Van Der KleijFG , BeusekampBJ , KerstensMN , De JongPE , et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. Diabetologia2002;45(4):535-41. [MEDLINE: 12032630]">Luik 2002</a>; <a href="./references#CD006763-bbs2-0013" title="MillerJA . Renal responses to sodium restriction in patients with early diabetes mellitus. Journal of the American Society of Nephrology1997;8(5):749-55. [MEDLINE: 9176844]">Miller 1997</a>; <a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a>). </p> <p>In one cross‐over study, insufficient details were reported on whether a washout period was applied between treatment arms and was therefore judged to have an unclear risk of bias (<a href="./references#CD006763-bbs2-0003" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_X 1989</a>). </p> <p>In the remaining 12 studies, no washout period was applied between cross‐over phases resulting in possible carryover effects, and therefore they were judged to be at high risk of bias (<a href="./references#CD006763-bbs2-0006" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Micro 2001</a>; <a href="./references#CD006763-bbs2-0007" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Normo 2001</a>; <a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>; <a href="./references#CD006763-bbs2-0012" title="MillerJA . Sympathetic vasoconstrictive responses to high- and low-sodium diets in diabetic and normal subjects. American Journal of Physiology1995;269(2 Pt 2):R380-8. [MEDLINE: 7653660]">Miller 1995</a>; <a href="./references#CD006763-bbs2-0015" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Micro 1998</a>; <a href="./references#CD006763-bbs2-0016" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Normo 1998</a>; <a href="./references#CD006763-bbs2-0017" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Micro 2004</a>; <a href="./references#CD006763-bbs2-0018" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Normo 2004</a>; <a href="./references#CD006763-bbs2-0019" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Adva Alb 1998</a>; <a href="./references#CD006763-bbs2-0020" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Micro 1998</a>; <a href="./references#CD006763-bbs2-0021" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Normo 1998</a>). </p> <p>No other potential sources of bias were identified.</p> </section> </section> </section> <section id="CD006763-sec-0058"> <h3 class="title" id="CD006763-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD006763-tbl-0001"><b>Summary of findings 1</b> Reduced salt intake versus usual or high salt intake for preventing diabetic kidney disease and its progression</a>; <a href="./full#CD006763-tbl-0002"><b>Summary of findings 2</b> Net change in blood pressure in hypertensive and normotensive participants with a reduced salt intake versus usual or high salt intake for preventing diabetic kidney disease and its progression</a>; <a href="./full#CD006763-tbl-0003"><b>Summary of findings 3</b> Net change in blood pressure in participants with type 1 or type 2 diabetes with a reduced salt diet versus usual or high salt intake for preventing diabetic kidney disease and its progression</a> </p> <p>As studies were not of sufficient duration to test the efficacy of salt reduction on outcome measurements such as heart attacks, end‐stage kidney disease (ESKD) or death, changes in salt intake on BP and surrogate markers of CKD in participants were considered in evaluating the evidence for this review. </p> <section id="CD006763-sec-0059"> <h4 class="title">Urinary sodium excretion</h4> <p>In 17 studies (<a href="./appendices#CD006763-sec-0098">Appendix 5</a>), the median 24‐hour UNa on the usual or high salt intake was 203 mmol (4.7 g sodium/day) with a range of 159 to 361 mmol/24 hours (3.7 to 8.3 g sodium/day). The median 24‐hour UNa on a low salt diet was 73 mmol (1.7 g sodium/day) with a range of 14 to 164 mmol (0.6 to 7.1 g sodium/day). The median net change in 24‐hour UNa was 123 mmol/24 hours (5.4 g sodium/day) with a range of 51 to 337 mmol (2.2 to 14.7 g sodium/day). Four studies (<a href="./references#CD006763-bbs2-0006" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Micro 2001</a>; <a href="./references#CD006763-bbs2-0007" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Normo 2001</a>; <a href="./references#CD006763-bbs2-0017" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Micro 2004</a>; <a href="./references#CD006763-bbs2-0018" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Normo 2004</a>) were excluded from these calculations as they only provided graphical data of urinary sodium concentrations.<br/><br/>In the seven long‐term studies (<a href="./references#CD006763-bbs2-0002" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_P 1989</a>; <a href="./references#CD006763-bbs2-0003" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_X 1989</a>; <a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>; <a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>; <a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a>), the median 24‐hour UNa on the high salt diet was 202 mmol, with a range of 188 to 224 mmol and on the low salt diet was 123 mmol, ranging from 80 to 164 mmol. The median net change in 24‐hour UNa was 76 mmol, ranging from 51 to 124 mmol. </p> <p>In short‐term studies, data were available from 10 studies (<a href="./references#CD006763-bbs2-0001" title="De'OliveiraJM , PriceDA , FisherND , AllanDR , McKnightJA , WilliamsGH , et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney International1997;52(3):771-7. [MEDLINE: 9291199]">De'Oliveira 1997</a>; <a href="./references#CD006763-bbs2-0010" title="Lopes de FariaJB , FriedmanR , deCosmoS , DoddsRA , MorttonJJ , VibertiGC . Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake. Nephron1997;76(4):411-7. [MEDLINE: 9274838]">Lopes De Faria 1997</a>; <a href="./references#CD006763-bbs2-0011" title="LuikPT , HoogenbergK , Van Der KleijFG , BeusekampBJ , KerstensMN , De JongPE , et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. Diabetologia2002;45(4):535-41. [MEDLINE: 12032630]">Luik 2002</a>; <a href="./references#CD006763-bbs2-0012" title="MillerJA . Sympathetic vasoconstrictive responses to high- and low-sodium diets in diabetic and normal subjects. American Journal of Physiology1995;269(2 Pt 2):R380-8. [MEDLINE: 7653660]">Miller 1995</a>; <a href="./references#CD006763-bbs2-0013" title="MillerJA . Renal responses to sodium restriction in patients with early diabetes mellitus. Journal of the American Society of Nephrology1997;8(5):749-55. [MEDLINE: 9176844]">Miller 1997</a>; <a href="./references#CD006763-bbs2-0015" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Micro 1998</a>; <a href="./references#CD006763-bbs2-0016" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Normo 1998</a>; <a href="./references#CD006763-bbs2-0019" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Adva Alb 1998</a>; <a href="./references#CD006763-bbs2-0020" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Micro 1998</a>; <a href="./references#CD006763-bbs2-0021" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Normo 1998</a>). Median 24‐hour UNa on the usual or high salt diet was 224 mmol, with a range of 159 to 361 mmol and on the low salt diet was 32 mmol, with a range of 14 to 99 mmol. The median net change in 24‐hour UNa was 187 mmol, with a range of 86 to 337 mmol. </p> <p>In 10 studies, which included participants with hypertension (<a href="./references#CD006763-bbs2-0001" title="De'OliveiraJM , PriceDA , FisherND , AllanDR , McKnightJA , WilliamsGH , et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney International1997;52(3):771-7. [MEDLINE: 9291199]">De'Oliveira 1997</a>; <a href="./references#CD006763-bbs2-0002" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_P 1989</a>; <a href="./references#CD006763-bbs2-0003" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_X 1989</a>; <a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>; <a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>; <a href="./references#CD006763-bbs2-0019" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Adva Alb 1998</a>; <a href="./references#CD006763-bbs2-0020" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Micro 1998</a>; <a href="./references#CD006763-bbs2-0021" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Normo 1998</a>), the median net change in 24‐hour UNa was 89 mmol, with a range of 51 to 181 mmol. In seven studies (<a href="./references#CD006763-bbs2-0010" title="Lopes de FariaJB , FriedmanR , deCosmoS , DoddsRA , MorttonJJ , VibertiGC . Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake. Nephron1997;76(4):411-7. [MEDLINE: 9274838]">Lopes De Faria 1997</a>; <a href="./references#CD006763-bbs2-0011" title="LuikPT , HoogenbergK , Van Der KleijFG , BeusekampBJ , KerstensMN , De JongPE , et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. Diabetologia2002;45(4):535-41. [MEDLINE: 12032630]">Luik 2002</a>; <a href="./references#CD006763-bbs2-0012" title="MillerJA . Sympathetic vasoconstrictive responses to high- and low-sodium diets in diabetic and normal subjects. American Journal of Physiology1995;269(2 Pt 2):R380-8. [MEDLINE: 7653660]">Miller 1995</a>; <a href="./references#CD006763-bbs2-0013" title="MillerJA . Renal responses to sodium restriction in patients with early diabetes mellitus. Journal of the American Society of Nephrology1997;8(5):749-55. [MEDLINE: 9176844]">Miller 1997</a>; <a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a>; <a href="./references#CD006763-bbs2-0015" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Micro 1998</a>; <a href="./references#CD006763-bbs2-0016" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Normo 1998</a>) which included participants with normal BP levels, the median net change in 24‐hour UNa was 211 mmol with a range of 107 to 337 mmol. </p> <p>In seven studies of participants with type 1 diabetes, the median net change in 24‐hour UNa was 211 mmol with a range of 107 to 337 mmol (<a href="./references#CD006763-bbs2-0010" title="Lopes de FariaJB , FriedmanR , deCosmoS , DoddsRA , MorttonJJ , VibertiGC . Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake. Nephron1997;76(4):411-7. [MEDLINE: 9274838]">Lopes De Faria 1997</a>; <a href="./references#CD006763-bbs2-0011" title="LuikPT , HoogenbergK , Van Der KleijFG , BeusekampBJ , KerstensMN , De JongPE , et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. Diabetologia2002;45(4):535-41. [MEDLINE: 12032630]">Luik 2002</a>; <a href="./references#CD006763-bbs2-0012" title="MillerJA . Sympathetic vasoconstrictive responses to high- and low-sodium diets in diabetic and normal subjects. American Journal of Physiology1995;269(2 Pt 2):R380-8. [MEDLINE: 7653660]">Miller 1995</a>; <a href="./references#CD006763-bbs2-0013" title="MillerJA . Renal responses to sodium restriction in patients with early diabetes mellitus. Journal of the American Society of Nephrology1997;8(5):749-55. [MEDLINE: 9176844]">Miller 1997</a>; <a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a>; <a href="./references#CD006763-bbs2-0015" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Micro 1998</a>; <a href="./references#CD006763-bbs2-0016" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Normo 1998</a>). In 10 studies of participants with type 2 diabetes, the median net change in 24‐hour UNa was 89 mmol with a range of 51 to 181 mmol (<a href="./references#CD006763-bbs2-0001" title="De'OliveiraJM , PriceDA , FisherND , AllanDR , McKnightJA , WilliamsGH , et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney International1997;52(3):771-7. [MEDLINE: 9291199]">De'Oliveira 1997</a>; <a href="./references#CD006763-bbs2-0002" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_P 1989</a>; <a href="./references#CD006763-bbs2-0003" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_X 1989</a>; <a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>; <a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>; <a href="./references#CD006763-bbs2-0019" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Adva Alb 1998</a>; <a href="./references#CD006763-bbs2-0020" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Micro 1998</a>; <a href="./references#CD006763-bbs2-0021" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Normo 1998</a>). </p> </section> <section id="CD006763-sec-0060"> <h4 class="title">Effects of different sodium intakes on blood pressure</h4> <p>All studies that could be included in the meta‐analyses reported measurements of BP as SBP and DBP or MAP (defined as DBP + (SBP‐DBP)/3). </p> <section id="CD006763-sec-0061"> <h5 class="title">Systolic blood pressure</h5> <p>Data from 12 studies were available for analysis of SBP. Combining data on longer‐term (up to 12 weeks) with short‐term use (one week) of low sodium intake demonstrated that a low sodium intake diet may reduce SBP by 7.36 mm Hg (<a href="./references#CD006763-fig-0006" title="">Analysis 1.1</a> (12 studies): MD ‐7.36 mm Hg, 95% CI ‐10.75 to ‐3.98; I² = 74%). In longer studies, low sodium intake may reduce SBP by 6.15 mm Hg (<a href="./references#CD006763-fig-0006" title="">Analysis 1.1</a>.1 (7 studies): MD ‐6.12 mm Hg, 95% CI ‐9.27 to ‐3.03; I² = 12%) while in one‐week studies, low sodium intake may reduce SBP by 8.43 mm Hg (<a href="./references#CD006763-fig-0006" title="">Analysis 1.1</a>.2 (5 studies): MD ‐8.43 mm Hg, 95% CI ‐14.37 to ‐2.48; I² = 88%). There was considerable heterogeneity in the analysis of one‐week studies (I² = 88%) but not in the analysis of longer studies (I² = 12%). </p> <p>The reduction in SBP with a low sodium diet may not differ between studies of participants with (<a href="./references#CD006763-fig-0011" title="">Analysis 1.6</a>.2) or without albuminuria (<a href="./references#CD006763-fig-0011" title="">Analysis 1.6</a>.1) at study enrolment. </p> </section> <section id="CD006763-sec-0062"> <h5 class="title">Diastolic blood pressure</h5> <p>Data from 12 studies were available for analysis of DBP (<a href="./references#CD006763-fig-0008" title="">Analysis 1.3</a>). Combining longer‐term and short‐term use of low sodium intake demonstrated that a low sodium intake diet may reduce DBP by 3.17 mm Hg (<a href="./references#CD006763-fig-0008" title="">Analysis 1.3</a> (12 studies): MD ‐3.17 mm Hg, 95% CI ‐4.58 to ‐1.76; I² = 54%). In longer studies, low sodium intake may reduce DBP by 3.41 mm Hg (<a href="./references#CD006763-fig-0008" title="">Analysis 1.3</a>.1 (7 studies): MD ‐3.41 mm Hg, 95% CI ‐5.56 to ‐1.27; I² = 41%) while in one‐week studies, low sodium intake also may reduce DBP by 2.95 mm Hg (<a href="./references#CD006763-fig-0008" title="">Analysis 1.3</a>.2 (5 studies): MD ‐2.95 mm Hg, 95% CI ‐4.96 to ‐0.94; I² = 70%). There was substantial heterogeneity in the analysis of one‐week studies (I² = 70%), but this was lower in the analysis of longer studies (I² = 41%). </p> <p>The reduction in DBP with a low sodium diet may not differ between studies of participants with (<a href="./references#CD006763-fig-0012" title="">Analysis 1.7</a>.2) or without albuminuria (<a href="./references#CD006763-fig-0012" title="">Analysis 1.7</a>.1) at study enrolment. </p> </section> <section id="CD006763-sec-0063"> <h5 class="title">Mean arterial pressure</h5> <p>Data from 13 studies were available for analysis of MAP. Both long‐term and short‐term use of low sodium intake may reduce MAP by 3.01 mm Hg (<a href="./references#CD006763-fig-0010" title="">Analysis 1.5</a> (13 studies): MD ‐3.01 mm Hg, 95% CI ‐4.95 to ‐1.07; I² = 63%). In longer studies, low sodium intake may reduce MAP by 4.60 mm Hg (<a href="./references#CD006763-fig-0010" title="">Analysis 1.5</a>.1 (4 studies): MD ‐4.60 mm Hg, 95% CI ‐7.26 to ‐1.94; I² = 28%). In one‐week studies, low sodium intake may reduce MAP by 2.37 mm Hg (<a href="./references#CD006763-fig-0010" title="">Analysis 1.5</a>.2 (9 studies): MD ‐2.37 mm Hg, 95% CI ‐4.75 to ‐0.01; I² = 65%). There was substantial heterogeneity in the analysis of one‐week studies (I = 65%), but this was not seen in the analysis of longer studies (I² = 28%). </p> <p>The reduction in MAP with a low sodium intake may be greater in studies of participants with albuminuria at study enrolment (<a href="./references#CD006763-fig-0013" title="">Analysis 1.8</a>.2 (7 studies): MD ‐5.40 mm Hg, 95% CI ‐7.72 to ‐3.08) compared with those without albuminuria (<a href="./references#CD006763-fig-0013" title="">Analysis 1.8</a>.1 (3 studies): MD ‐0.11 mm Hg, 95% CI ‐2.27 to 2.05) at study enrolment. </p> </section> <section id="CD006763-sec-0064"> <h5 class="title">Certainty of the evidence</h5> <p>The certainty of the evidence is summarised in <a href="./full#CD006763-tbl-0001">summary of findings Table 1</a>. All results were considered to be at low certainty evidence because of the small numbers of included participants, heterogeneity between study results and increased risk of bias. </p> </section> </section> <section id="CD006763-sec-0065"> <h4 class="title">Effects of different sodium intakes on blood pressure in hypertensive and normotensive participants </h4> <section id="CD006763-sec-0066"> <h5 class="title">Hypertensive participants</h5> <p>Five studies evaluated the effects of salt restriction on SBP and DBP in hypertensive participants (<a href="./references#CD006763-bbs2-0002" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_P 1989</a>; <a href="./references#CD006763-bbs2-0003" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_X 1989</a>; <a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>; <a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a>), and three studies evaluated MAP (<a href="./references#CD006763-bbs2-0001" title="De'OliveiraJM , PriceDA , FisherND , AllanDR , McKnightJA , WilliamsGH , et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney International1997;52(3):771-7. [MEDLINE: 9291199]">De'Oliveira 1997</a>; <a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>). </p> <p>In hypertensive participants, salt restriction may reduce SBP by 6.45 mm Hg (<a href="./references#CD006763-fig-0021" title="">Analysis 2.1</a>.1 (5 studies): MD ‐6.45 mm Hg, 95% CI ‐11.47 to ‐1.42; I² = 41%), DBP by 3.15 mm Hg (<a href="./references#CD006763-fig-0022" title="">Analysis 2.2</a>.1 (5 studies): MD ‐3.15 mm Hg, 95% CI ‐6.49 to ‐0.18; I ² = 60%), and MAP by 4.88 mm Hg (<a href="./references#CD006763-fig-0023" title="">Analysis 2.3</a>.1 (3 studies): MD ‐4.88 mm Hg, 95% CI ‐10.39 to ‐0.63; I² = 54%). There was moderate heterogeneity in the analyses. </p> </section> <section id="CD006763-sec-0067"> <h5 class="title">Normotensive participants</h5> <p>Five studies evaluated the effects of salt restriction in normotensive participants (<a href="./references#CD006763-bbs2-0006" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Micro 2001</a>; <a href="./references#CD006763-bbs2-0007" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Normo 2001</a>; <a href="./references#CD006763-bbs2-0011" title="LuikPT , HoogenbergK , Van Der KleijFG , BeusekampBJ , KerstensMN , De JongPE , et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. Diabetologia2002;45(4):535-41. [MEDLINE: 12032630]">Luik 2002</a>; <a href="./references#CD006763-bbs2-0015" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Micro 1998</a>; <a href="./references#CD006763-bbs2-0016" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Normo 1998</a>), and eight studies evaluated MAP (<a href="./references#CD006763-bbs2-0010" title="Lopes de FariaJB , FriedmanR , deCosmoS , DoddsRA , MorttonJJ , VibertiGC . Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake. Nephron1997;76(4):411-7. [MEDLINE: 9274838]">Lopes De Faria 1997</a>; <a href="./references#CD006763-bbs2-0012" title="MillerJA . Sympathetic vasoconstrictive responses to high- and low-sodium diets in diabetic and normal subjects. American Journal of Physiology1995;269(2 Pt 2):R380-8. [MEDLINE: 7653660]">Miller 1995</a>; <a href="./references#CD006763-bbs2-0013" title="MillerJA . Renal responses to sodium restriction in patients with early diabetes mellitus. Journal of the American Society of Nephrology1997;8(5):749-55. [MEDLINE: 9176844]">Miller 1997</a>; <a href="./references#CD006763-bbs2-0017" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Micro 2004</a>; <a href="./references#CD006763-bbs2-0018" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Normo 2004</a>; <a href="./references#CD006763-bbs2-0019" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Adva Alb 1998</a>; <a href="./references#CD006763-bbs2-0020" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Micro 1998</a>; <a href="./references#CD006763-bbs2-0021" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Normo 1998</a>). </p> <p>In normotensive participants, salt restriction may reduce SBP by 8.43 mm Hg (<a href="./references#CD006763-fig-0021" title="">Analysis 2.1</a>.2 (5 studies): MD ‐8.43 mm Hg, 95% CI ‐14.37 to ‐2.48; I² = 88%), reduce DBP by 2.95 mm Hg (<a href="./references#CD006763-fig-0022" title="">Analysis 2.2</a>.2 (5 studies): MD ‐2.95 mm Hg, 95% CI ‐4.96 to ‐0.94; I² = 70%), and MAP by 2.15 mm Hg (<a href="./references#CD006763-fig-0023" title="">Analysis 2.3</a>.2 (8 studies): MD ‐2.15 mm Hg, 95% CI ‐4.56 to ‐0.26; I² = 68%). There was substantial heterogeneity in the analyses. </p> </section> <section id="CD006763-sec-0068"> <h5 class="title">Certainty of the evidence</h5> <p>The certainty of the evidence is summarised in <a href="./full#CD006763-tbl-0002">summary of findings Table 2</a>. All results were considered to be of low certainty evidence because of the small numbers of included participants, heterogeneity between study results and increased risk of bias. </p> </section> </section> <section id="CD006763-sec-0069"> <h4 class="title">Effects of different sodium intakes on blood pressure in type 1 and type 2 diabetes</h4> <section id="CD006763-sec-0070"> <h5 class="title">Type 1 diabetes</h5> <p>Four studies evaluated the effects of salt restriction on SBP and DBP in participants with type 1 diabetes (<a href="./references#CD006763-bbs2-0011" title="LuikPT , HoogenbergK , Van Der KleijFG , BeusekampBJ , KerstensMN , De JongPE , et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. Diabetologia2002;45(4):535-41. [MEDLINE: 12032630]">Luik 2002</a>; <a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a>; <a href="./references#CD006763-bbs2-0015" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Micro 1998</a>; <a href="./references#CD006763-bbs2-0016" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Normo 1998</a>), and three studies reported the effects on MAP (<a href="./references#CD006763-bbs2-0010" title="Lopes de FariaJB , FriedmanR , deCosmoS , DoddsRA , MorttonJJ , VibertiGC . Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake. Nephron1997;76(4):411-7. [MEDLINE: 9274838]">Lopes De Faria 1997</a>; <a href="./references#CD006763-bbs2-0012" title="MillerJA . Sympathetic vasoconstrictive responses to high- and low-sodium diets in diabetic and normal subjects. American Journal of Physiology1995;269(2 Pt 2):R380-8. [MEDLINE: 7653660]">Miller 1995</a>; <a href="./references#CD006763-bbs2-0013" title="MillerJA . Renal responses to sodium restriction in patients with early diabetes mellitus. Journal of the American Society of Nephrology1997;8(5):749-55. [MEDLINE: 9176844]">Miller 1997</a>). </p> <p>Salt restriction may reduce SBP by 7.35 mm Hg (<a href="./references#CD006763-fig-0024" title="">Analysis 3.1</a>.1 (4 studies): MD ‐7.35 mm Hg, 95% CI ‐14.49 to ‐0.21; I² = 91%) and DBP by 3.20 mm Hg (<a href="./references#CD006763-fig-0025" title="">Analysis 3.2</a>.1 (4 studies): MD ‐3.20 mm Hg, 95% CI ‐5.16 to ‐1.23; I² = 62%), but may make little or no difference to MAP (<a href="./references#CD006763-fig-0026" title="">Analysis 3.3</a>.1 (3 studies): MD 0.08 mm Hg, 95% CI ‐4.95 to 2.08; I² = 8%). </p> </section> <section id="CD006763-sec-0071"> <h5 class="title">Type 2 diabetes</h5> <p>Eight studies evaluated the effects of salt restriction on SBP and DBP in participants with type 2 diabetes (<a href="./references#CD006763-bbs2-0002" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_P 1989</a>; <a href="./references#CD006763-bbs2-0003" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_X 1989</a>; <a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>; <a href="./references#CD006763-bbs2-0006" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Micro 2001</a>; <a href="./references#CD006763-bbs2-0007" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Normo 2001</a> <a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>), and 10 studies evaluated MAP (<a href="./references#CD006763-bbs2-0001" title="De'OliveiraJM , PriceDA , FisherND , AllanDR , McKnightJA , WilliamsGH , et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney International1997;52(3):771-7. [MEDLINE: 9291199]">De'Oliveira 1997</a>; <a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>; <a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>; <a href="./references#CD006763-bbs2-0017" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Micro 2004</a>; <a href="./references#CD006763-bbs2-0018" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Normo 2004</a>; <a href="./references#CD006763-bbs2-0019" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Adva Alb 1998</a>; <a href="./references#CD006763-bbs2-0020" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Micro 1998</a>; <a href="./references#CD006763-bbs2-0021" title="YoshiokaK , ImanishiM , KonishiY , SatoT , TanakaS , KimuraG , et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care1998;21(4):482-6. [MEDLINE: 9571328]">Yoshioka Normo 1998</a>). </p> <p>Salt restriction may reduce SBP by 7.35 mm Hg (<a href="./references#CD006763-fig-0024" title="">Analysis 3.1</a>,2 (8 studies): MD ‐7.35 mm Hg, 95% CI ‐10.32 to ‐4.38; I² = 22%), DBP by 3.04 mm Hg (<a href="./references#CD006763-fig-0025" title="">Analysis 3.2</a>.2 (8 studies): MD ‐3.04 mm Hg, 95% CI ‐5.20 to ‐0.89; I² = 57%), and MAP by 4.30 mm Hg (<a href="./references#CD006763-fig-0026" title="">Analysis 3.3</a>.2 (10 studies): MD ‐4.30 mm Hg, 95% CI ‐6.54 to ‐2.05; I = 56%). There was substantial heterogeneity in the analyses. </p> </section> <section id="CD006763-sec-0072"> <h5 class="title">Certainty of the evidence</h5> <p>The certainty of the evidence is summarised in <a href="./full#CD006763-tbl-0003">summary of findings Table 3</a>. All results were considered to be of low certainty evidence because of the small numbers of included participants, heterogeneity between study results and increased risk of bias. </p> </section> </section> <section id="CD006763-sec-0073"> <h4 class="title">Concomitant interventions with renin‐angiotensin system blockers</h4> <p>Salt restriction has been demonstrated to reduce BP when the RAS is blocked (<a href="./references#CD006763-bbs2-0056" title="MacGregorG , MarkanduND , SingerDR , CappuccioFP , ShoreAC , SagnellaGA . Moderate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension: a double blind study. British Medical Journal Clinical Research Ed1987;294(6571):531-4. [MEDLINE: 3103761]">MacGregor 1987</a>). Three of seven studies in the long‐term studies included participants treated with RAS blockers (<a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>). Therefore we recalculated pooled data, excluding data from these studies. Pooled estimates of the changes in the remaining four studies showed reductions in SBP of 5.55 mm Hg (<a href="./references#CD006763-fig-0007" title="">Analysis 1.2</a>.1 (4 studies): MD ‐5.55 mm Hg, 95% CI ‐11.73 to ‐0.62) and in DBP of 2.26 mm Hg (<a href="./references#CD006763-fig-0009" title="">Analysis 1.4</a>.1 (4 studies): MD ‐2.26m Hg, 95% CI ‐6.54 to 2.02) with 95% CIs that overlapped those of <a href="./references#CD006763-fig-0006" title="">Analysis 1.1</a> and <a href="./references#CD006763-fig-0008" title="">Analysis 1.3</a> (which included the studies using ACEi or ARBs), suggesting that RAS blockade may not result in further reductions in SBP and DBP in this small group of studies. </p> </section> <section id="CD006763-sec-0074"> <h4 class="title">Effects of altering salt intake on measurements of kidney function</h4> <p>Pooled analysis of seven studies showed that salt restriction may reduce CrCl by 6.05 mL/min (<a href="./references#CD006763-fig-0014" title="">Analysis 1.9</a> (7 studies): MD ‐6.05 mL/min, 95% CI ‐10.00 to ‐2.10; I² = 0%). However, pooled analysis of 12 studies of eGFR found that there may make little or no difference in eGFR in these studies (<a href="./references#CD006763-fig-0015" title="">Analysis 1.10</a> (12 studies): MD ‐1.87 mL/min/1.73 m², 95% CI ‐5.05 to 1.31; I² = 32%). </p> <p>Eight studies reported change in ERPF. Salt restriction may not alter ERPF in longer studies (<a href="./references#CD006763-fig-0016" title="">Analysis 1.11</a>.1 (8 studies): MD ‐0.73 mL/min, 95% CI ‐2.83 to 1.37; I² = 0%) or short‐term studies (<a href="./references#CD006763-fig-0016" title="">Analysis 1.11</a>.2 (5 studies): MD ‐0.14 mL/min, 95% CI ‐68.26 to 67.98; I² = 82%). </p> </section> <section id="CD006763-sec-0075"> <h4 class="title">Effects of altering salt intake on urinary albumin and protein excretion</h4> <p>Eight studies presented data on changes in urinary albumin or urinary protein excretion during salt restriction (<a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>; <a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>; <a href="./references#CD006763-bbs2-0011" title="LuikPT , HoogenbergK , Van Der KleijFG , BeusekampBJ , KerstensMN , De JongPE , et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. Diabetologia2002;45(4):535-41. [MEDLINE: 12032630]">Luik 2002</a>; <a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a>; <a href="./references#CD006763-bbs2-0017" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Micro 2004</a>; <a href="./references#CD006763-bbs2-0018" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Normo 2004</a>. The data for individual studies are shown in <a href="./appendices#CD006763-sec-0099">Appendix 6</a>. These studies reported the data in ways which were not suitable for meta‐analysis, so pooled analyses were not performed. One study of type 2 diabetics (<a href="./references#CD006763-bbs2-0017" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Micro 2004</a>) reported salt restriction may reduce UAE in patients with microalbuminuria, while two other studies reported no change in UAE in type 1 diabetics with (<a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a>) or without (<a href="./references#CD006763-bbs2-0011" title="LuikPT , HoogenbergK , Van Der KleijFG , BeusekampBJ , KerstensMN , De JongPE , et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. Diabetologia2002;45(4):535-41. [MEDLINE: 12032630]">Luik 2002</a>) microalbuminuria. Salt restriction may reduce UAE in type 2 diabetics receiving RAS blockade (<a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>) but may not reduce UAE in those not receiving RAS blockade (<a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>). </p> </section> <section id="CD006763-sec-0076"> <h4 class="title">Effects of altering salt intake on HbA1c</h4> <p>Six studies reported the results of HbA1c at the beginning and end of the study (<a href="./references#CD006763-bbs2-0002" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_P 1989</a>; <a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>; <a href="./references#CD006763-bbs2-0010" title="Lopes de FariaJB , FriedmanR , deCosmoS , DoddsRA , MorttonJJ , VibertiGC . Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake. Nephron1997;76(4):411-7. [MEDLINE: 9274838]">Lopes De Faria 1997</a>; <a href="./references#CD006763-bbs2-0011" title="LuikPT , HoogenbergK , Van Der KleijFG , BeusekampBJ , KerstensMN , De JongPE , et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. Diabetologia2002;45(4):535-41. [MEDLINE: 12032630]">Luik 2002</a>; <a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a>). </p> <p>Pooled analysis showed no difference in HbA1c during salt restriction, suggesting that there were no alterations in diabetic control during the studies (<a href="./references#CD006763-fig-0017" title="">Analysis 1.12</a> (6 studies): MD ‐0.62, 95% CI ‐1.49 to 0.26; I² = 95%). There was significant heterogeneity between studies; however, the exclusion of one small study (<a href="./references#CD006763-bbs2-0010" title="Lopes de FariaJB , FriedmanR , deCosmoS , DoddsRA , MorttonJJ , VibertiGC . Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake. Nephron1997;76(4):411-7. [MEDLINE: 9274838]">Lopes De Faria 1997</a>) (which showed a small decrease of 3% in HbA1c) removed the heterogeneity between studies. </p> </section> <section id="CD006763-sec-0077"> <h4 class="title">Effects of altering salt intake on body weight</h4> <p>Twelve studies reported data on body weight (<a href="./references#CD006763-bbs2-0002" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_P 1989</a>; <a href="./references#CD006763-bbs2-0003" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_X 1989</a>; <a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>; <a href="./references#CD006763-bbs2-0010" title="Lopes de FariaJB , FriedmanR , deCosmoS , DoddsRA , MorttonJJ , VibertiGC . Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake. Nephron1997;76(4):411-7. [MEDLINE: 9274838]">Lopes De Faria 1997</a>; <a href="./references#CD006763-bbs2-0011" title="LuikPT , HoogenbergK , Van Der KleijFG , BeusekampBJ , KerstensMN , De JongPE , et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. Diabetologia2002;45(4):535-41. [MEDLINE: 12032630]">Luik 2002</a>; <a href="./references#CD006763-bbs2-0013" title="MillerJA . Renal responses to sodium restriction in patients with early diabetes mellitus. Journal of the American Society of Nephrology1997;8(5):749-55. [MEDLINE: 9176844]">Miller 1997</a>; <a href="./references#CD006763-bbs2-0014" title="MulhauserI , PrangeK , SawickiPT , BenderR , DworschakA , SchadenW , et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia1996;39(2):212-9. [MEDLINE: 8635674]">Mulhauser 1996</a>; <a href="./references#CD006763-bbs2-0015" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Micro 1998</a>; <a href="./references#CD006763-bbs2-0016" title="TrevisanR , BruttomessoD , VedovatoM , BroccoS , PiantaA , MazzonC , et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes1998;47(8):1347-53. [MEDLINE: 9703338]">Trevisan Normo 1998</a>; <a href="./references#CD006763-bbs2-0017" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Micro 2004</a>; <a href="./references#CD006763-bbs2-0018" title="VedovatoM , LeporeG , CoracinaA , DodesiniAR , JoriE , TiengoA , et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia2004;47(2):300-3. [MEDLINE: 14704836]">Vedovato Normo 2004</a>). </p> <p>Salt restriction lowered body weight by ‐1.21 kg (<a href="./references#CD006763-fig-0018" title="">Analysis 1.13</a> (12 studies): MD ‐1.21 kg, 95% CI ‐1.73 to ‐0.68; I² = 76%). This effect was primarily due to changes in short‐term studies, with minimal weight change with salt restriction in longer studies (<a href="./references#CD006763-fig-0018" title="">Analysis 1.13</a>.1 (5 studies): MD ‐0.35 kg, 95% CI ‐1.63 to 0.94; I² = 0%) compared with short‐term studies (<a href="./references#CD006763-fig-0018" title="">Analysis 1.13</a>.2 (7 studies): MD ‐1.30 kg, 95% CI ‐1.89 to ‐0.72; I² = 86%) suggesting that these changes are likely to be due to a reduction in extracellular volume. </p> </section> <section id="CD006763-sec-0078"> <h4 class="title">Adverse effects</h4> <p>Only two studies reported adverse effects (<a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>). These studies reported orthostatic hypotension was identified in 11% of participants receiving a reduced sodium diet compared with 4% receiving a normal sodium diet. It occurred most frequently (21%) in those receiving a low salt diet together with hydrochlorothiazide. </p> </section> <section id="CD006763-sec-0079"> <h4 class="title">Fixed effects versus random effects model</h4> <p>To ensure robustness, we performed analyses using both the fixed effect and random effects models. </p> <p>In all studies (<a href="./references#CD006763-fig-0006" title="">Analysis 1.1</a> to <a href="./references#CD006763-fig-0010" title="">Analysis 1.5</a>), reductions in SBP, DBP and MAP with salt restrictions were similar using both analyses. Compared with the initial version of this review, the addition of <a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a> and <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a> to the subgroup analysis resulted in the net change in DBP in longer studies no longer differing between the fixed effects (MD ‐3.71 mm Hg, 95% CI ‐5.29 to ‐2.14) and random effects models (MD ‐3.41 mm Hg, 95% CI ‐5.56 to ‐1.27) with both models showing a reduction in DBP with salt restriction. </p> <p>In studies of hypertensive and normotensive participants, salt restriction reduced SBP, DBP and MAP in both groups (<a href="./references#CD006763-fig-0021" title="">Analysis 2.1</a>; <a href="./references#CD006763-fig-0022" title="">Analysis 2.2</a>; <a href="./references#CD006763-fig-0023" title="">Analysis 2.3</a>). Among the subgroup of hypertensive participants, the net change in DBP did not differ between fixed (MD ‐3.78 mm Hg, 95% CI ‐5.73 to ‐1.84) and random effects models (MD ‐3.15 mm Hg, 95% CI ‐6.49 to 0.18) but the 95% CIs crossed 1 with the random effects model. There was no difference between subgroups with either analysis. </p> <p>In studies of type 1 and type 2 diabetics, changes in SBP, DBP and MAP with salt restriction were similar between fixed and random effects analyses (<a href="./references#CD006763-fig-0024" title="">Analysis 3.1</a>; <a href="./references#CD006763-fig-0025" title="">Analysis 3.2</a>; <a href="./references#CD006763-fig-0026" title="">Analysis 3.3</a>). </p> </section> <section id="CD006763-sec-0080"> <h4 class="title">Investigation of sources of heterogeneity</h4> <p>We assessed heterogeneity using the I² statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than sampling error (<a href="./references#CD006763-bbs2-0051" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [MEDLINE: 12958120]">Higgins 2003</a>). We investigated levels of heterogeneity considered to be substantial (50% to 90%) or considerable (75% to 100%). For the outcomes of SBP, DBP and MAP, there was considerable heterogeneity among short‐term studies (SBP: 88%; DBP: 70%; MAP: 65%), but this variation was not seen in long‐term studies (SBP: 12%; DBP: 41%; MAP: 28%). While variations in MDs between studies within short‐term studies did not appear to be related to either the reduction in urinary sodium achieved or to the minimum urine sodium recorded (<a href="./appendices#CD006763-sec-0100">Appendix 7</a>), the range of net change in UNa recorded in short‐term studies (86 to 337 mmol) was much greater than that seen in long‐term studies (51 to 124 mmol) suggesting that differences in study design contributed to heterogeneity between studies. </p> <p>We also examined whether there were differences in the degree of heterogeneity among cross‐over studies in which there was or was not a washout period between the first and second parts of the cross‐over. For SBP (<a href="./references#CD006763-fig-0019" title="">Analysis 1.14</a>) but not for MAP (<a href="./references#CD006763-fig-0020" title="">Analysis 1.15</a>), there was less heterogeneity among cross‐over studies with washout compared with those without washout. However, the results for SBP largely mirrored those seen overall for SBP among long‐term and short‐term studies (<a href="./references#CD006763-fig-0006" title="">Analysis 1.1</a>). For MAP, there remained heterogeneity of 69% among cross‐over studies with washout (<a href="./references#CD006763-fig-0020" title="">Analysis 1.15</a>.1) and 66% among studies without washout (<a href="./references#CD006763-fig-0020" title="">Analysis 1.15</a>.2). Overall, we were not able to identify specific sources for heterogeneity between studies. However, most studies were at high risk of bias for most criteria (<a href="#CD006763-fig-0002">Figure 2</a>). </p> </section> <section id="CD006763-sec-0081"> <h4 class="title">Sensitivity analyses</h4> <p>We planned to perform sensitivity analyses to explore the influence of the following factors on effect size. </p> <p> <ul id="CD006763-list-0014"> <li> <p>Repeating the analysis excluding unpublished studies: This was not done as we did not identify any unpublished studies. </p> </li> <li> <p>Repeating the analysis taking account of the risk of bias, as specified: This was not done as studies were at unclear or high risk of bias for most criteria (<a href="#CD006763-fig-0002">Figure 2</a>; <a href="#CD006763-fig-0004">Figure 4</a>; <a href="#CD006763-fig-0005">Figure 5</a>) </p> </li> <li> <p>Repeating the analysis excluding any long duration or large studies to establish how much they dominate the results: We re‐analysed the results after excluding three studies with long durations and more than 30 participants (<a href="./references#CD006763-bbs2-0002" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_P 1989</a>; <a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>). The results for SBP for long‐term studies with these three studies excluded (MD ‐5.57 mm Hg, 95% CI ‐9.51 to ‐1.62) did not differ from the overall results (MD ‐6.12 m Hg, 95% CI ‐9.02 to ‐3.22). The MD for DBP in long‐term studies (MD ‐5.02 mm Hg, 95% CI ‐9.38 to ‐0.65) was slightly higher than for the overall results (MD ‐3.71 mm Hg, 95% CI ‐5.29 to ‐2.14), but the CIs overlapped. Therefore we did not identify that the exclusion of these three studies made major changes to the results. </p> </li> </ul> </p> <div class="figure" id="CD006763-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Net change with altering salt diet, outcome: 1.1 Systolic BP." data-id="CD006763-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Net change with altering salt diet, outcome: 1.1 Systolic BP. </p> </div> </div> </div> <div class="figure" id="CD006763-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Net change with altering salt diet, outcome: 1.5 MAP." data-id="CD006763-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Net change with altering salt diet, outcome: 1.5 MAP.</p> </div> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006763-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006763-sec-0082"></div> <section id="CD006763-sec-0083"> <h3 class="title" id="CD006763-sec-0083">Summary of main results</h3> <p>This systematic review identified 21 studies (313 participants) from 13 RCTs, which evaluated the efficacy of reducing salt intake on BP and kidney function in participants with type 1 or type 2 diabetes. This update added two additional studies (<a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>). All studies were of short duration, and no studies addressed the outcomes of cardiovascular events (stroke, heart failure, myocardial infarction). </p> <p> <ul id="CD006763-list-0015"> <li> <p>The median net reduction in all studies in 24‐hour UNa during the low sodium intake was 123 mmol/24 hours (5.4 g sodium/day) with a range of 51 to 337 mmol (2.2 to 14.7 g sodium/day). The median net reduction in seven long‐term studies (treatment duration four to 12 weeks) was 76 mmol, ranging from 51 to 124 mmol. The median net reduction in 10 short‐term studies (treatment duration five to seven days) was 187 mmol, with a range of 86 to 337 mmol. Data were only available graphically in four studies. </p> </li> <li> <p>Sodium restriction may reduce SBP by 7.36 mm Hg, DBP by 3.17 mm Hg and MAP by 3.01 mm Hg in all participants (low certainty evidence). </p> </li> <li> <p>No differences were identified between hypertensive and normotensive participants or between participants with type 1 or type 2 diabetes (low certainty evidence). </p> </li> <li> <p>During salt restriction, SBP and DBP may be reduced by similar amounts in studies, including participants with or without microalbuminuria at study enrolment. However, the reduction in MAP may be greater in participants with microalbuminuria at study enrolment compared with those without microalbuminuria. </p> </li> <li> <p>UAE was formally assessed in only eight studies. During salt restriction, UAE fell in four studies (<a href="./appendices#CD006763-sec-0099">Appendix 6</a>). </p> </li> <li> <p>There may be a small reduction in body weight during salt restriction, but this was largely seen in studies of one to two weeks rather than in longer studies (low certainty evidence). </p> </li> <li> <p>There may be no differences in HbA1c during salt restriction (low certainty evidence).</p> </li> <li> <p>There may be no changes to GFR or ERPF though CrCl may be reduced by 6 mL/min during salt restriction (low certainty evidence). </p> </li> <li> <p>Adverse effects were only reported in two of 21 studies. Two studies reported that orthostatic hypotension was identified more frequently in participants receiving a reduced sodium diet with or without hydrochlorothiazide compared with those receiving a normal sodium diet (<a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>). </p> </li> </ul> </p> </section> <section id="CD006763-sec-0084"> <h3 class="title" id="CD006763-sec-0084">Overall completeness and applicability of evidence</h3> <p>The available data from this systematic review of RCTs of salt restriction indicate that lowering sodium intake may reduce BP in participants with type 1 and type 2 diabetes, with and without hypertension and with normal or slightly abnormal kidney function (G1, A1 or A2 on the KDIGO classification) (<a href="./references#CD006763-bbs2-0054" title="Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International2020;98(45):S1-115. [MEDLINE: 32998798]">KDIGO 2020</a>). No studies were identified in this patient group which evaluated salt restriction in participants with greater degrees of reduced kidney function. Two additional studies were added in this update (<a href="./references#CD006763-bbs2-0008" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak HTZ 2014</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>), but these data did not change the conclusions of the initial version of the review. The duration of the studies (maximum duration three months) and the small size of the studies (maximum number of 45 participants) did not allow any assessment of important patient‐centred outcomes, including death and CVD. The majority of studies were cross‐over studies, with only one or two weeks in each phase of the study. Seventeen studies provided information on the sodium intakes in each group, with four studies providing graphical information only. Twelve studies provided information on SBP and DBP, while nine provided information only on MAP. Data on kidney function were more limited, with only 12 studies providing information on eGFR and an additional three studies providing information on CrCl. Overall, eGFR was maintained unchanged during the study periods. Limited data were available to assess the effect of salt reduction on UAE. UAE is important in monitoring the progression of kidney disease in participants with diabetes and is an independent predictor of CVD (<a href="./references#CD006763-bbs2-0053" title="HillegeHL , FidlerV , DiercksGF , Van GilstWH , De ZeeuwD , Van VeldhuisenDJ , et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation2002;106(14):1777-82. [MEDLINE: 12356629]">Hillege 2002</a>). We found only eight studies in this meta‐analysis where UAE and/or protein excretion was measured, and it was not possible to perform pooled analysis due to variations in the way data were reported. Four of the eight studies demonstrated a reduction in UAE with salt restriction. Most studies were performed before 2000, and participants did not routinely receive RAS inhibitors. RAS inhibition with either ACEi or ARBs is now recommended for all diabetic patients with albuminuria since RAS blockade slows the deterioration in kidney function (<a href="./references#CD006763-bbs2-0054" title="Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International2020;98(45):S1-115. [MEDLINE: 32998798]">KDIGO 2020</a>). Since high salt intake reduces the efficacy of these agents on BP (<a href="./references#CD006763-bbs2-0056" title="MacGregorG , MarkanduND , SingerDR , CappuccioFP , ShoreAC , SagnellaGA . Moderate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension: a double blind study. British Medical Journal Clinical Research Ed1987;294(6571):531-4. [MEDLINE: 3103761]">MacGregor 1987</a>), guidelines recommend that salt intake be reduced to 5 g/day (sodium intake &lt; 2 g or &lt; 90 mmol/day) (<a href="./references#CD006763-bbs2-0054" title="Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International2020;98(45):S1-115. [MEDLINE: 32998798]">KDIGO 2020</a>). While such reductions in salt intake may be achievable in the short term, it is hard to maintain long‐term reductions without intensive input from dietitians and easily interpretable information about the salt content of commonly used foods. </p> </section> <section id="CD006763-sec-0085"> <h3 class="title" id="CD006763-sec-0085">Quality of the evidence</h3> <p>There are important limitations to this review. The number of studies on the effects of salt reduction in diabetics was limited, and the majority of available studies were of short duration with few included participants. The results show considerable heterogeneity, particularly among studies lasting only one to two weeks. The small number of studies limits the ability to explore potential sources of this heterogeneity. It is likely that differing methodologies and degrees and duration of salt restriction affect heterogeneity. Studies varied from five days to 12 weeks, and longer studies had more modest changes in salt intake. Several short studies restricted levels of salt intake to as low as 0.6 g/day, followed by loading of up to 20 g/day of salt. Acute, large changes in dietary salt intake such as this will stimulate the RAS and increase sympathetic activity. This will have an impact on the effects on BP and renal haemodynamics. This is demonstrated by the lack of any difference in SBP or DBP between shorter and longer studies, despite a change in median salt intake of almost double that seen in the longer studies. While MDs in MAP did differ slightly between long‐term and short‐term studies, the CIs overlapped. </p> <p>Outcome measurements were mostly restricted to measurements of BP and surrogate markers of kidney function. We did not find any available data on outcome measurements such as time to ESKD, CVD and death. 24‐hour UNa is a surrogate method of estimating salt intake, but since approximately 90% of the salt we eat is excreted through the kidneys, 24‐hour UNa provides an accurate assessment of sodium intake. Compared with all other methods, e.g. dietary record or recall, measuring 24‐hour UNa excretion is the most accurate and accepted method for assessing dietary salt intake. </p> <p>GRADE assessment of the included outcomes showed that the certainty of the evidence was low for all outcomes when all studies were included (<a href="./full#CD006763-tbl-0001">summary of findings Table 1</a>), when studies evaluated participants with or without hypertension (<a href="./full#CD006763-tbl-0002">summary of findings Table 2</a>) and when studies evaluated participants with type 1 and type 2 diabetes (<a href="./full#CD006763-tbl-0003">summary of findings Table 3</a>). Studies were downgraded for risk of bias issues (allocation concealment and blinding), for heterogeneity between studies and for imprecision based on small numbers of enrolled participants. </p> </section> <section id="CD006763-sec-0086"> <h3 class="title" id="CD006763-sec-0086">Potential biases in the review process</h3> <p>The search strategy was comprehensive and covers all important and relevant databases. We do not believe we have missed any potentially relevant studies. Of the studies identified, we have endeavoured to obtain all data by contacting the authors, but we were unsuccessful in obtaining additional data. Therefore, there is a small potential for bias in the available outcome data. Data collection was undertaken using a piloted data extraction form. Data analysis and assessment of the quality of studies were all performed in duplicate with a third party for disagreement resolution. We do not believe any other biases could have been introduced. </p> </section> <section id="CD006763-sec-0087"> <h3 class="title" id="CD006763-sec-0087">Agreements and disagreements with other studies or reviews</h3> <p>A recently published systematic review of RCTs has evaluated the effect of reducing salt intake on BP in people with type 2 diabetes (<a href="./references#CD006763-bbs2-0062" title="RenJ , QinL , LiX , ZhaoR , WuZ , MaY . Effect of dietary sodium restriction on blood pressure in type 2 diabetes: a meta-analysis of randomized controlled trials. Nutrition, Metabolism &amp; Cardiovascular Diseases2021;31(6):1653-61. [MEDLINE: 33838996]">Ren 2021</a>). This review included eight RCTs (10 studies) in adults, who underwent a period of salt restriction of at least one week, the sodium intake was calculated from 24‐hour UNa measurements, and the differences in SBP and DBP between low and usual sodium diets were reported or could be calculated. Six studies (<a href="./references#CD006763-bbs2-0002" title="DodsonPM , BeeversM , HallworthR , WebberleyMJ , FletcherRF , TaylorKG . Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ1989;298(6668):227-30. [MEDLINE: 2493869]">Dodson_P 1989</a>; <a href="./references#CD006763-bbs2-0004" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Losartan 2002</a>; <a href="./references#CD006763-bbs2-0005" title="HoulihanC , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]. Nephrology2000;5(3):A71. [CENTRAL: CN-00509238] HoulihanCA , AkdenizA , TsalamandrisC , CooperME , JerumsG , GilbertRE . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care2002;25(6):1072-7. [MEDLINE: 12032117]HoulihanCA , AllenT , HoveyA , JenkinsM , CooperM , JerumsG . Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]. Journal of the American Society of Nephrology2000;11(Sept):116A. [CENTRAL: CN-00615874] HoulihanCA , AllenTJ , BaxterAL , PanangiotopoulosS , CasleyDJ , CooperME , et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care2002;25(4):663-71. [MEDLINE: 11919122]">Houlihan Placebo 2002</a>; <a href="./references#CD006763-bbs2-0006" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Micro 2001</a>; <a href="./references#CD006763-bbs2-0007" title="ImanishiM , YoshiokaK , OkumuraM , KonishiY , OkadaN , MorikawaT , et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care2001;24(1):111-6. [MEDLINE: 11194215]">Imanishi Normo 2001</a>; <a href="./references#CD006763-bbs2-0009" title="BinnenmarsSH , CorpeleijnE , KwakernaakAJ , TouwDJ , KemaIP , LavermanGD , et al. Impact of moderate sodium restriction and hydrochlorothiazide on iodine excretion in diabetic kidney disease: data from a randomized cross-over trial. Nutrients2019;11(9):2204. [MEDLINE: 31547438]HumaldaJK , KeyzerCA , BinnenmarsSH , KwakernaakAJ , SlagmanMC , LavermanGD , et al. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions. Nutrition Metabolism &amp; Cardiovascular Diseases2016;26(8):689-96. [MEDLINE: 27266988]HumaldaJK , Seiler-MulerS , KwakernaakAJ , VervloetMG , NavisG , FliserD , et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine2016;95(46):e5003. [MEDLINE: 27861335]HumaldaJK , SeilerS , KwakernaakAJ , VervloetMG , NavisG , HeineGH , et al. Response of fibroblast growth factor 23 to sodium interventions in diabetic nephropathy and arterial hypertension [abstract no: PUB535]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):1012A. KwakernaakAJ , KrikkenJA , BinnenmarsSH , VisserFW , HemmelderMH , WoittiezAJ , et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2014;2(5):385-95. [MEDLINE: 24795252]">Kwakernaak Placebo 2014</a>) were also included in this Cochrane review. The authors found that salt restriction reduced SBP and DBP by 5.6 mm Hg and 1.7 mm Hg, respectively, compared with reductions of 7.2 mm Hg and 3 mm Hg found in our Cochrane review. Recent systematic reviews of RCTs in people with CKD and not on dialysis found that reducing salt intake lowers SBP and DBP by similar amounts to those seen in our review(<a href="./references#CD006763-bbs2-0040" title="GarafaloC , BorrelliS , ProvenzanoM , De StefanoT , VitaC , ChoidiniP , et al. Dietary salt restriction in chronic kidney disease: a meta-analysis of randomized clinical trials. Nutrients2018;10(6):Article No: 732. [MEDLINE: 29882800]">Garafalo 2018</a>; <a href="./references#CD006763-bbs2-0057" title="McMahonEJ , CampbellKL , BauerJD , MudgeDW , KellyJT . Altered dietary salt intake for people with chronic kidney disease. Cochrane Database of Systematic Reviews2021, Issue Issue 6. Art. No: CD010070. [DOI: 10.1002/14651858.CD010070.pub3]">McMahon 2021</a>). In systematic reviews of studies in people with normal kidney function, reducing sodium intake consistently reduces BP levels with greater reductions in hypertension participants (<a href="./references#CD006763-bbs2-0045" title="GraudalNA , Hubeck-GraudalT , JurgensG . Effects of low sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol and triglyceride. Cochrane Database of Systematic Reviews2020, Issue 12. Art. No: CD004022. [DOI: 10.1002/14651858.CD004022.pub5]">Graudal 2020</a>; <a href="./references#CD006763-bbs2-0048" title="HeFJ , MacGregorGA . How far should salt intake be reduced?Hypertension2003;42(6):1093-9. [MEDLINE: 14610100]">He 2003</a>). In this review, we found that urinary protein excretion was reduced in four of the eight studies in which this outcome was reported. This outcome was not reported in <a href="./references#CD006763-bbs2-0062" title="RenJ , QinL , LiX , ZhaoR , WuZ , MaY . Effect of dietary sodium restriction on blood pressure in type 2 diabetes: a meta-analysis of randomized controlled trials. Nutrition, Metabolism &amp; Cardiovascular Diseases2021;31(6):1653-61. [MEDLINE: 33838996]">Ren 2021</a>, which reviewed studies of participants with type 2 diabetes. Systematic reviews in people with CKD (<a href="./references#CD006763-bbs2-0040" title="GarafaloC , BorrelliS , ProvenzanoM , De StefanoT , VitaC , ChoidiniP , et al. Dietary salt restriction in chronic kidney disease: a meta-analysis of randomized clinical trials. Nutrients2018;10(6):Article No: 732. [MEDLINE: 29882800]">Garafalo 2018</a>; <a href="./references#CD006763-bbs2-0057" title="McMahonEJ , CampbellKL , BauerJD , MudgeDW , KellyJT . Altered dietary salt intake for people with chronic kidney disease. Cochrane Database of Systematic Reviews2021, Issue Issue 6. Art. No: CD010070. [DOI: 10.1002/14651858.CD010070.pub3]">McMahon 2021</a>) have found that reduced salt intake reduces urinary protein excretion by about 30%. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006763-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD006763-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full#CD006763-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006763-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full#CD006763-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006763-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full#CD006763-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Net change with altering salt diet, outcome: 1.1 Systolic BP." data-id="CD006763-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Net change with altering salt diet, outcome: 1.1 Systolic BP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full#CD006763-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Net change with altering salt diet, outcome: 1.5 MAP." data-id="CD006763-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Net change with altering salt diet, outcome: 1.5 MAP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full#CD006763-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Net change with altering salt diet, Outcome 1: Systolic BP" data-id="CD006763-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Net change with altering salt diet, Outcome 1: Systolic BP</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Net change with altering salt diet, Outcome 2: Systolic BP (excluding studies using RAS)" data-id="CD006763-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Net change with altering salt diet, Outcome 2: Systolic BP (excluding studies using RAS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Net change with altering salt diet, Outcome 3: Diastolic BP" data-id="CD006763-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Net change with altering salt diet, Outcome 3: Diastolic BP</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Net change with altering salt diet, Outcome 4: Diastolic BP (excluding studies using RAS)" data-id="CD006763-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Net change with altering salt diet, Outcome 4: Diastolic BP (excluding studies using RAS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Net change with altering salt diet, Outcome 5: MAP" data-id="CD006763-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Net change with altering salt diet, Outcome 5: MAP</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Net change with altering salt diet, Outcome 6: Systolic BP according to presence/absence of albuminuria at enrolment" data-id="CD006763-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Net change with altering salt diet, Outcome 6: Systolic BP according to presence/absence of albuminuria at enrolment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Net change with altering salt diet, Outcome 7: Diastolic BP according to presence/absence of albuminuria at enrolment" data-id="CD006763-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Net change with altering salt diet, Outcome 7: Diastolic BP according to presence/absence of albuminuria at enrolment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Net change with altering salt diet, Outcome 8: MAP according to the presence/absence of albuminuria at enrolment" data-id="CD006763-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Net change with altering salt diet, Outcome 8: MAP according to the presence/absence of albuminuria at enrolment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Net change with altering salt diet, Outcome 9: Creatinine clearance" data-id="CD006763-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Net change with altering salt diet, Outcome 9: Creatinine clearance</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Net change with altering salt diet, Outcome 10: Glomerular filtration rate" data-id="CD006763-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Net change with altering salt diet, Outcome 10: Glomerular filtration rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Net change with altering salt diet, Outcome 11: Effective renal plasma flow" data-id="CD006763-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Net change with altering salt diet, Outcome 11: Effective renal plasma flow </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Net change with altering salt diet, Outcome 12: HbA1c" data-id="CD006763-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Net change with altering salt diet, Outcome 12: HbA1c</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Net change with altering salt diet, Outcome 13: Body weight" data-id="CD006763-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Net change with altering salt diet, Outcome 13: Body weight</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Net change with altering salt diet, Outcome 14: Systolic BP in cross‐over studies with or without washout between interventions" data-id="CD006763-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Net change with altering salt diet, Outcome 14: Systolic BP in cross‐over studies with or without washout between interventions </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Net change with altering salt diet, Outcome 15: MAP in cross‐over studies with or without washout between study periods" data-id="CD006763-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Net change with altering salt diet, Outcome 15: MAP in cross‐over studies with or without washout between study periods </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Net change in BP in hypertensive and normotensive participants, Outcome 1: Systolic BP" data-id="CD006763-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Net change in BP in hypertensive and normotensive participants, Outcome 1: Systolic BP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Net change in BP in hypertensive and normotensive participants, Outcome 2: Diastolic BP" data-id="CD006763-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Net change in BP in hypertensive and normotensive participants, Outcome 2: Diastolic BP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Net change in BP in hypertensive and normotensive participants, Outcome 3: MAP" data-id="CD006763-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Net change in BP in hypertensive and normotensive participants, Outcome 3: MAP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Net change in BP in type 1 and type 2 diabetes, Outcome 1: Systolic BP" data-id="CD006763-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Net change in BP in type 1 and type 2 diabetes, Outcome 1: Systolic BP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Net change in BP in type 1 and type 2 diabetes, Outcome 2: Diastolic BP" data-id="CD006763-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Net change in BP in type 1 and type 2 diabetes, Outcome 2: Diastolic BP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Net change in BP in type 1 and type 2 diabetes, Outcome 3: MAP" data-id="CD006763-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Net change in BP in type 1 and type 2 diabetes, Outcome 3: MAP</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Net change in BP in type 1 and type 2 diabetes, Outcome 4: HbA1c" data-id="CD006763-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Net change in BP in type 1 and type 2 diabetes, Outcome 4: HbA1c</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006763-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/urn:x-wiley:14651858:media:CD006763:CD006763-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Adverse events, Outcome 1: Orthostatic hypotension" data-id="CD006763-fig-0028" src="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_t/tCD006763-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Adverse events, Outcome 1: Orthostatic hypotension</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/media/CDSR/CD006763/image_n/nCD006763-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006763-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Reduced salt intake versus usual or high salt intake for preventing diabetic kidney disease and its progression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Reduced salt intake versus usual or high salt intake for preventing diabetic kidney disease and its progression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with diabetes with or without CKD </p> <p><b>Setting:</b> inpatients and outpatients<br/><b>Intervention:</b> reduced salt intake<br/><b>Comparison:</b> usual or high salt intake </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with usual or high salt intake</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with reduced salt intake</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systolic BP: long‐term studies</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean systolic BP was 6.15 mm Hg lower with a reduced salt intake (9.27 lower to 3.03 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systolic BP: short‐term studies</p> <p>Duration: 1 week</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean systolic BP was 8.43 mm Hg lower with a reduced salt intake (9.6 lower to 5.81 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diastolic BP: long‐term studies</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean diastolic BP was 3.41 mm Hg lower with a reduced salt intake (5.56 lower to 1.27 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diastolic BP: short‐term studies</p> <p>Duration: 1 week</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean diastolic BP was 2.95 mm Hg lower with a reduced salt intake (4.96 lower to 0.94 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MAP: all studies</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean MAP was 3.01 mm Hg lower with a reduced salt intake (4.95 lower to 1.07 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>421 (13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFF: all studies</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean GFR was 1.78 mL/min/1.73 m² lower<br/>with a reduced salt intake (4.21 lower to 0.65 higher) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>392 (12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body weight: all studies</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean body weight was 1.21 kg lower with a reduced salt intake (1.73 lower to 0.68 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>454 (12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/><br/><b>CKD:</b> Chronic kidney disease; <b>CI:</b> Confidence interval; <b>RCT:</b> Randomised controlled trial; <b>BP:</b> Blood pressure; <b>MD:</b> Mean difference; <b>MAP:</b> Mean arterial pressure; <b>GFR:</b> Glomerular filtration rate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Heterogeneity between studies </p> <p><sup>2</sup> High or unclear risk of bias for allocation concealment and blinding due to study design (cross‐over studies) with small numbers of enrolled participants </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Reduced salt intake versus usual or high salt intake for preventing diabetic kidney disease and its progression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full#CD006763-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006763-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Net change in blood pressure in hypertensive and normotensive participants with a reduced salt intake versus usual or high salt intake for preventing diabetic kidney disease and its progression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Net change in BP in hypertensive and normotensive participants with a reduced salt intake versus usual or high salt intake for preventing diabetic kidney disease and its progression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with diabetes with or without CKD<br/><b>Setting:</b> inpatients and outpatients<br/><b>Intervention:</b> reduced salt intake<br/><b>Comparison:</b> usual or high salt intake </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with usual or high salt intake</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with reduced salt intake</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Systolic BP</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean systolic BP in <b>hypertensive</b> patients was 6.45 mm Hg lower with a reduced salt intake (11.69 lower to 3.61 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean systolic BP in <b>normotensive</b> patients was 8.43 mm Hg lower with a reduced salt intake (9.6 lower to 5.81 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diastolic BP</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean diastolic BP in <b>hypertensive</b> patients was 3.15 mm Hg lower with a reduced salt intake (6.49 lower to 0.18 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean diastolic BP in <b>normotensive</b> patients was 2.95 mm Hg lower with a reduced salt intake (4.11 lower to 2 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MAP</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean MAP in <b>hypertensive</b> patients was 4.88 mm Hg lower with a reduced salt intake (10.39 lower to 0.63 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The MAP in <b>normotensive</b> patients was 2.15 mm Hg lower with a reduced salt intake (4.56 lower to 0.26 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BP:</b> Blood pressure; <b>CKD:</b> Chronic kidney disease; <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>MAP:</b> Mean arterial pressure </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Heterogeneity between studies </p> <p><sup>2</sup> High or unclear risk of bias for allocation concealment and blinding due to study design (cross‐over studies) with small numbers of enrolled participants </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Net change in blood pressure in hypertensive and normotensive participants with a reduced salt intake versus usual or high salt intake for preventing diabetic kidney disease and its progression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full#CD006763-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006763-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Net change in blood pressure in participants with type 1 or type 2 diabetes with a reduced salt diet versus usual or high salt intake for preventing diabetic kidney disease and its progression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Net change in BP in participants with type 1 and type 2 diabetes with a reduced salt intake versus usual or high salt intake for preventing diabetic kidney disease and its progression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with diabetes with or without CKD<br/><b>Setting:</b> inpatients and outpatients<br/><b>Intervention:</b> reduced salt intake<br/><b>Comparison:</b> usual or high salt intake </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with usual or high salt intake</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with reduced salt intake</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Systolic BP</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean systolic BP in patients with <b>type 1 diabetes</b> was 7.35 mm Hg lower with a reduced salt intake (14.49 lower to 0.21 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean systolic BP in patients with <b>type 2 diabetes</b> was 7.35 mm Hg lower with a reduced salt intake (10.32 lower to 4.38 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diastolic BP:</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean diastolic BP in patients with <b>type 1 diabetes</b> was 3.20 mm Hg lower with a reduced salt intake (5.16 lower to 1.23 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean diastolic BP in patients with <b>type 2 diabetes</b> was 3.04 mm Hg lower with a reduced salt intake (5.20 lower to 0.89 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MAP</p> <p>Duration: up to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean MAP in patients with <b>type 1 diabetes</b> was 0.08 mm Hg higher with a reduced salt intake (1.92 lower to 2.08 higher) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean MAP in patients with <b>type 2 diabetes</b> was 4.03 mm Hg lower with a reduced salt intake (6.54 lower to 2.05 lower) compared to a usual or high salt intake </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>359 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BP:</b> Blood pressure; <b>CKD:</b> Chronic kidney disease; <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>MAP:</b> Mean arterial pressure </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Heterogeneity between studies </p> <p><sup>2</sup> High or unclear risk of bias for allocation concealment and blinding due to study design (cross‐over studies) with small numbers of enrolled participants </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Net change in blood pressure in participants with type 1 or type 2 diabetes with a reduced salt diet versus usual or high salt intake for preventing diabetic kidney disease and its progression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/full#CD006763-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006763-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Net change with altering salt diet</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Systolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.36 [‐10.75, ‐3.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Long‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.15 [‐9.27, ‐3.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Short‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.43 [‐14.37, ‐2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Systolic BP (excluding studies using RAS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.44 [‐11.83, ‐3.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Long‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.55 [‐11.73, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Short‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.43 [‐14.37, ‐2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Diastolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.17 [‐4.58, ‐1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Long‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.41 [‐5.56, ‐1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Short‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.95 [‐4.96, ‐0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Diastolic BP (excluding studies using RAS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.76 [‐4.53, ‐0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Long‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.26 [‐6.54, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Short‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.95 [‐4.96, ‐0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 MAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.01 [‐4.95, ‐1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Long‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.60 [‐7.26, ‐1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Short‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.37 [‐4.75, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Systolic BP according to presence/absence of albuminuria at enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.63 [‐10.19, ‐3.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 No albuminuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.08 [‐15.42, ‐0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Albuminuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.85 [‐8.76, ‐2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Diastolic BP according to presence/absence of albuminuria at enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.54 [‐4.92, ‐2.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 No albuminuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.58 [‐5.75, ‐1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Albuminuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.48 [‐5.45, ‐1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 MAP according to the presence/absence of albuminuria at enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 No albuminuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐2.27, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Albuminuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.40 [‐7.72, ‐3.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Creatinine clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.05 [‐10.00, ‐2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Long‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.66 [‐18.55, 5.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Short‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.23 [‐12.88, ‐1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Glomerular filtration rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.87 [‐5.05, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Long‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.07 [‐5.29, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Short‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.26 [‐9.93, 3.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Effective renal plasma flow <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.74 [‐17.08, 3.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Long‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.73 [‐2.83, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Short‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐68.26, 67.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐1.49, 0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Long‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.35, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Short‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.44 [‐4.47, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.21 [‐1.73, ‐0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Long‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐1.63, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Short‐term studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐1.89, ‐0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Systolic BP in cross‐over studies with or without washout between interventions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Studies with washout</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.33 [‐7.32, ‐1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Studies without washout</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.92 [‐15.67, ‐4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 MAP in cross‐over studies with or without washout between study periods <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Studies with washout</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.52 [‐5.50, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Studies without washout</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.32 [‐6.28, ‐0.36]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Net change with altering salt diet</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006763-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Net change in BP in hypertensive and normotensive participants</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Systolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.65 [‐11.69, ‐3.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Hypertensive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.45 [‐11.47, ‐1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Normotensive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.43 [‐14.37, ‐2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Diastolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.08 [‐4.74, ‐1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Hypertensive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.15 [‐6.49, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Normotensive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.95 [‐4.96, ‐0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 MAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.74 [‐4.97, ‐0.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Hypertensive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.88 [‐10.39, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Normotensive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.15 [‐4.56, 0.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Net change in BP in hypertensive and normotensive participants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006763-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Net change in BP in type 1 and type 2 diabetes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Systolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.36 [‐10.75, ‐3.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Type 1 diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.35 [‐14.49, ‐0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Type 2 diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.35 [‐10.32, ‐4.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Diastolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.17 [‐4.58, ‐1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Type 1 diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.20 [‐5.16, ‐1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Type 2 diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.04 [‐5.20, ‐0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 MAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.01 [‐4.95, ‐1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Type 1 diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐1.92, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Type 2 diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.30 [‐6.54, ‐2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐1.49, 0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Type 1 diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.94 [‐2.38, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Type 2 diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.58, 0.34]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Net change in BP in type 1 and type 2 diabetes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006763-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Orthostatic hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.81, 7.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006763.pub3/references#CD006763-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006763.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD006763-note-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD006763-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006763-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006763-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD006763-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="id#CD006763-note-0017">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ja#CD006763-note-0015">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD006763-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD006763-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="nl#CD006763-note-0018">Nederlands</a> </li> <li class="section-language"> <a class="" href="pt#CD006763-note-0008">Português</a> </li> <li class="section-language"> <a class="" href="th#CD006763-note-0014">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD006763-note-0013">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006763\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006763\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006763\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006763\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006763\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006763\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006763\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006763\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006763\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006763\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006763\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006763\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006763\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006763\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006763\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006763\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006763\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006763\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006763.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006763.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006763.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006763.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006763.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725899358"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006763.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725899362"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006763.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e867d7d119371',t:'MTc0MDcyNTg5OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 